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Bone Mineral Density 
(BMD) 
DXA calculates BMD (grams per square centimeter) as bone 
mineral content (BMC; in grams) divided by the projected bone area 
(square centimeters) (Leslie et al., 2012). 
Dual-Energy X-ray 
Absorptiometry (DXA) 
DXA is widely used for measurement of bone mineral density.  
DXA allows accurate diagnosis of osteoporosis, estimation of 
fracture risk and monitoring of patients undergoing treatment (El 
Maghraoui & Roux, 2008). 
Diabetes Mellitus 
Diabetes mellitus is a metabolic disorder with heterogeneous 
aetiologies which is characterised by chronic hyperglycemia and 
disturbances of carbohydrate, fat and protein metabolism resulting 
from defects in insulin secretion, insulin action or both (Amod et al., 
2012). 
Femur 
The femur is the longest and heaviest bone in the human body.  
The superior end of the femur consists of a head, and the greater 
and lesser trochanter.  The head is attached to the femoral body or 
shaft by the neck of the femur (Cooper et al., 2015). 




The lumbar spine consists of 5 moveable vertebrae numbered L1-
L5.  Lumbar disks are well designed to sustain compression loads 
but rely on posterior elements to limit axial rotation (Bogduk, 
2016).   
Osteopenia 
Osteopenia is referred to as decrease in bone mineral density 
which if continues leads to osteoporosis (Asif et al., 2015). 
Osteopenia diagnosis 
Osteopenia is defined as a bone density between 1.0 and 2.5 SD 
below the mean for young adult women (Syed & Khan, 2002). 
Osteoporosis  
Osteoporosis is often called the “silent disease,” because bone loss 
usually occurs gradually over time without symptoms.  Osteoporosis 
is defined as a combination of reduced bone mass and altered bone 
quality, with microarchitectural abnormalities, resulting in 
decreased bone strength with an increased risk of fractures 
(Jackuliak & Payer, 2014). 
Osteoporosis diagnosis 
The diagnosis of osteoporosis based on a T-score of ≤ −2.5 is and 
should remain one important way to identify an individual with an 
increased risk for fracture (Siris et al., 2014).  
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Peak Bone Mass 
Wilken et al., (2010) mentioned in an article that although research 
varies on the age at which peak BMD is reached, most suggest peak 
is reached somewhere between the ages of 20 and 30 years. They 
also mentioned that some investigators suggest that 95% of peak 
BMD is reached by age 17 years for females and two to three years 
later for males, while others suggest PBM is reached by age 30 years 
for most bone sites (Wilken et al., 2010). 
Recommended sites 
It is recommended that bone density at the lumbar spine be 
evaluated from the first to the fourth lumbar vertebrae.  At the hip, 
the diagnosis of osteoporosis can be based on the T-score obtained 
at the femoral neck, total hip, or trochanteric regions (Syed & Kahn, 
2002).  
Region of Interest 
The software marks regions of interest in the spine and hip. The 
spine region of interest consists of the L1 through L4 vertebrae.  The 
hip regions of interest include the femoral neck, trochanter and total 
hip (El Maghraoui & Roux, 2008). 




The T-score is defined as the number of standard deviations the 
patient’s BMD is above or below the sex-matched mean reference 
value of young adults. The T-score thus provides a comparison of 
the patient’s BMD to the mean peak bone mass (Syed & Khan, 
2002).  
Type 1 Diabetes Mellitus 
and Type 2 Diabetes 
Mellitus 
The aetiological types of diabetes are type 1, type 2, other specific 
types and gestational diabetes.  Patients with any form of diabetes 
may require insulin treatment at some stage of their disease.  Such 
use of insulin does not, of itself, allow for aetiological classification.  
Type 1 diabetes results from pancreatic beta-cell destruction.  Type 
2 diabetes is the most common aetiological type and is predominated 
by disorders of insulin action (insulin resistance), and with insulin 
deficiency relative to a predominant secretory defect (i.e. disorders 
of insulin action and secretion) (Amod et al., 2012).  
Z-score 
The Z-score is the number of standard deviations above or below 
the expected BMD for the patient’s age and sex (Qaseem et al., 
2017).    
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Diabetes mellitus is a serious medical condition that occurs when the body cannot utilise 
glucose normally.  There are two main types of diabetes, known as type 1 diabetes mellitus and 
type 2 diabetes mellitus.  Type 2 diabetes mellitus is the most common type of diabetes which 
can have serious complications if not treated.   
 
Osteoporosis/osteopenia (low bone mass) are hidden, major health concerns for our society as 
a result of their quiescence nature of the bone loss process with no signs or symptoms until a 
fracture occurs.  
 
Non-invasive bone densitometry utilising X-ray absorptiometry enables accurate evaluation of 
bone mass and the diagnosis of osteoporosis in asymptomatic individuals prior to fracture.  
Bone mineral density is a vital component in the diagnosis and management of osteoporosis 
regarding bone strength, since fracture risk increases exponentially as bone mineral density 
decreases.  A DXA scan was performed on each subject.  The sites used in this study included 
the femoral neck (left and right), total hip (left and right) and the AP lumbar spine. 
 
This was a retrospective study.  Data of 140 Black female subjects were obtained from a 
database.  Ninety-one subjects were previously diagnosed with type 2 diabetes mellitus and 
acted as the test group, whilst 49 subjects had no diagnosis of diabetes mellitus and acted as 
the test group.   The T-scores of the test group and the control group were compared according 
to the guidelines of the World Health Organization.  These two groups were further divided 
into two subgroups according to age, as proposed by the National Osteoporosis Foundation of 
South Africa.  Subjects  ≥ 50 years were added in the calculations for the T-score, whilst 
subjects < 50 years were added in the calculations for Z-score. 
 
The aim of this study was to address the effect of type 2 diabetes mellitus on bone mineral 
density in middle-aged Black South African women.  A literature review was conducted to 
identify data sources for this ethnic group.   
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Statistical analysis was used to determine whether numerical variables followed a normal 
distribution pattern. Numerical values used included age, height, weight, BMI, T-score, Z-score 
and BMD. Descriptive statistics (means and standard deviations and percentiles) were used to 
calculate for numerical data, whilst frequencies and percentages were calculated for categorical 
data.  The test and control groups were compared with calculations from the independent T-
test to test for differences between mean values, whilst the Mann Whitney-U test was used to 
identify differences between the median values.  A significance level (α) of 0.05 was used, 
where p≥0.05 indicates no significant difference in the mean or median values of the two 
groups, and p< 0.05 indicates significant differences.  Fisher’s exact test was used to compare 
percentages of the T-score and Z-score in the two groups with the same significant level (α) p 
0.05 to determine the difference between the proportions of the two groups.  
 
The results of the test group compared with the control group according to the WHO definition 
of diagnosis with regards to the T-score showed no significant difference in the bone mineral 
density in the different areas.  Osteopenia was more prevalent than Osteoporosis in both groups.   
 
The results of the subjects ≥50 years’ T-score diagnosis according to the NOFSA guidelines 
indicate no significant difference between the proportions of the two groups, accept at the right 
femoral neck.  
 
There was no significant difference between the proportions of the two groups at the Z-score 
for women < 50 years. 
 
Although the difference was not statistically significant between the T-score, Z-score and BMD 
between the two groups, there is evidence of low bone mass (osteopenia) in general for this 
population.  It has been observed that type 2 diabetes mellitus negatively affects bone strength, 
regardless of bone mineral density. Furthermore, diabetes mellitus is a risk factor for 
osteoporosis and fractures, and that fractures can occur at higher bone mineral density levels 
in patients with diabetes mellitus. 
 













Diabetes mellitus (DM) is a metabolic disorder with heterogeneous aetiologies which is 
characterised by chronic hyperglycemia and disturbances of carbohydrate, fat and protein 
metabolism resulting from defects in insulin secretion, insulin action or both.  The long-term 
effects of DM include the development of retinopathy, nephropathy and neuropathy.  People 
with diabetes are also at increased risk of other diseases, which include cardiac, peripheral 
arterial and cerebrovascular diseases (Amod et al., 2012).   
 
Zheng et al. (2018) state that genetic predisposition partly determines individual 
susceptibility to type 2 diabetes mellitus (T2DM). An unhealthy diet (inadequate protein, 
calcium and vit D intake, etc.) and a sedentary lifestyle are important drivers of the current 
global epidemic. Early developmental factors (such as intrauterine exposures) also have a 
role in susceptibility to T2DM later in life. 
 
According to Amod et al. (2012), several pathogenic processes are involved in the development 
of DM.  These processes destroy the function of the pancreatic beta cells, leading to consequent 
insulin deficiency (type 1 diabetes mellitus; T1DM), and others can result in resistance to 
insulin actions (insulin resistance/insulin insensitivity - T2DM).  The abnormalities of 




carbohydrate, fat and protein metabolism are the result of inadequate insulin action within the 
target organs resulting in insensitivity to or the lack of insulin, or both.  
 
It is important to note that it may only be possible to establish the aetiology of diabetes 
retrospectively.  Diabetes, regardless of the aetiology, progresses through several clinical 
stages during its natural history, and an individual may progress from stage to stage in either 
direction.  Persons who have, or who are developing, diabetes can be categorised in a specific 
clinical stage according to their clinical characteristics, even in the absence of information 
about the underlying aetiology (Amod et al., 2012). 
 
DM adversely affects the skeleton and is associated with an increased risk of osteoporosis and 
fragility fractures (Hamann et al., 2012). The mechanisms underlying low bone strength are 
not fully understood but could include impaired accrual of peak bone mass (PBM) and diabetic 
complications, such as nephropathy. T1DM affects the skeleton more severely than T2DM, 
probably because of the lack of bone anabolic actions of insulin and other pancreatic hormones. 
Bone mass can remain high in patients with T2DM, but it does not protect against fractures, as 
bone quality is impaired. A physically active, healthy lifestyle and prevention of diabetic 
complications, along with calcium and vitamin D repletion, represent the mainstay of therapy 
for osteoporosis in patients with T1DM or T2DM. Assessment of bone mineral density (BMD) 
and other risk factors as part of the diagnostic procedure can help design tailored treatment 
plans for osteoporosis. Increased awareness of osteoporosis is needed in view of the growing 
and aging population of patients with DM.  
 
Osteoporosis is often referred to as “the silent disease,” as bone loss usually occurs gradually 
over time without symptoms.  Osteoporosis is defined as a combination of reduced bone mass 
and altered bone quality, with microarchitectural abnormalities, resulting in decreased bone 
strength with an increased risk of bone fractures.  Based on this definition, both bone density 
and quality, which encompass structural and material properties of bone, are important factors 
in determining bone strength (Jackuliak & Payer, 2014). As mentioned by Cadarette et al. 
(2000) osteoporosis frequently results in fractures that lead to pain, deformity and disability.  




Wrist, spine and hip fractures are frequently seen and are associated with an economic burden 
not only on the individual but also on society. 
 
Osteoporosis frequently results in fractures that lead to pain, deformity and disability. Wrist, 
spine and hip fractures are frequently seen and are associated with an economical burden not 
only on the individual but also on society (Cadarette et al., 2000).   
 
Along with the rising trend of DM, rapid urbanization has been observed,  Kapoor et al. (2014) 
predict that this demographic transition will largely take place in developing countries, 
particularly in Asia and Africa.  Throughout the process of development and urbanisation, 
national economies are shifting away from physically active economic activities like farming, 
mining, forestry, and so forth to more sedentary, often office-based, occupations (Kapoor et al, 
2014).  
 
In an article published by Padzys et al. (2015) in addition to sedentary lifestyles, diet also plays 
an important role in diabetes prevalence in Africa. Padzys et al. (2015) mention that population 
migration is leading to a nutritional transition in many African countries.  People arriving in 
town abandon their traditional lifestyles to adopt a diet rich in saturated animal products, salt, 
sugars and fats. Nutrition transition that results from urbanization are recognized as the two 
main factors responsible for the development of diabetes and obesity in Africa, especially in 
the Sub-Saharan area. In addition to urbanisation, the social status of the individual may also 
be a factor related to the prevalence of diabetes (Padzys et al., 2015). 
 
Goedecke et al. (2017) stated that women in Sub-Saharan Africa (SSA) also have a greater risk 
factor burden for T2DM than men.  The pathogenesis of diabetes differs between African and 
Caucasian women, with implications for risk assessment. It seems that African women are 
more insulin resistant than their Caucasian counterparts. Notably, women in SSA face the dual 
burden of T2DM and Human Immunodeficiency Virus/Acquired Immune Deficiency 
Syndrome (HIV/AIDS). HIV-positive women in SSA are typically young and obese, with the 
latter being exacerbated by anti-retroviral therapy (ART). Cultural perceptions regarding 




weight loss and limited financial resources are the major limitations to the management of 
T2DM (Goedecke et al., 2017).  
 
Ellis et al. (2019) have done research on black South African women (n=542) aged 29-65 years. 
They investigated the differences between BMD of HIV-positive and HIV-negative women. 
They found that low BMD was more common among HIV-positive than HIV-negative women. 
When the groups were matched for age and body mass index (BMI), only spine BMD was 
marginally lower in HIV-positive women. Older HIV-positive women with low educational 
status showed particular risk for low BMD. 
 
A study done by Hamill et al. (2017) suggested that, in urban, premenopausal, black South 
African women, HIV infection per se has no discernible effects on BMD status over a 12-
month period, but that exposure to Tenofovir Disoproxil Fumarate-based ART is associated 
with loss of BMD and an increase in bone turnover. 
 
Postmenopausal women with diabetes, who are a particularly fragile population because of the 
higher cardiovascular disease-related risk, are those at significantly higher risk for osteoporosis 
and its complications.  Sex hormones play a central role in the physiology of bone by direct 
and indirect mechanisms, and the abrupt loss of estrogens at menopause onset is considered 
the major reason for primary osteoporosis in women (Russo et al., 2014).  
 
Adolescents with T1DM may not reach potential PBM, putting them at greater fracture risk. 
In adults with T2DM, fracture risk is increased but not explained by the BMD measured by 
dual-energy X-ray absorptiometry (DXA), which is still considered the gold standard 
predictor of fracture (Sealand et al., 2013). DXA is widely used for the measurement of BMD. 
DXA allows accurate diagnosis of osteoporosis, estimation of fracture risk and monitoring of 
patients undergoing treatment. Additional features of DXA include measurement of BMD at 
multiple skeletal sites, safety of performance, short investigation time and ease of use (El 
Maghraoui & Roux, 2008). 
 




DXA is widely used for the measurement of BMD.  DXA allows accurate diagnosis of 
osteoporosis, estimation of fracture risk and monitoring of patients undergoing treatment. 
Additional features of DXA include measurement of BMD at multiple skeletal sites, safety of 
performance, short investigation time and ease of use (El Maghraoui & Roux, 2008).  
 
Recognition of various artefacts and pathologic processes that can falsely increase the 
measured BMD, is essential to accurate DXA scan analysis. Critical evaluation of the DXA 
scan image and careful appraisal of numeric data on the computer-generated printout by 
clinicians and radiology technologists are essential to ensure correct DXA scan interpretation 
(Theodorou & Theodorou, 2002).     
 
Another independent contributor to the assessment of fracture risk is trabecular bone score 
(TBS) and the fracture risk assessment tool (FRAX).  TBS is a grey‐level textural measurement 
derived from lumbar spine DXA images. It appears to be an index of bone microarchitecture 
that provides skeletal information additional to the standard BMD measurement.  Factors such 
as bone geometry, microdamage, mineralisation, bone turnover, age, family history of fracture, 
prior fracture, and fall risk contribute to the overall assessment of fracture risk. Several of these 
additional factors are captured by FRAX, which estimates the 10‐year probability of hip and 
major osteoporotic fracture based on the individual's risk factor profile (McCloskey et al., 
2016).    
 
In the United States of America (USA) today, the standard criterion for defining and diagnosing 
osteoporosis is the finding of a T-score of ≤ -2.5 at the lumbar spine, femur neck, or total hip 
by BMD testing (Siris et al., 2014). 
 
Early diagnosis is the key for appropriate osteoporosis management. To date, DXA is the most 
commonly used and validated method for bone densitometry in clinical practice. Nevertheless, 
some important limitations (e.g. use of ionising radiation, large size of the equipment, high 
costs and limited availability) do not allow DXA to be the true “gold standard technique” and 




make it unsuitable as a screening tool at the primary health care level for prevention purposes 
(Pisani et al., 2013). 
 
1.2 Purpose of the study 
 
Osteoporosis is a major public health problem because of its cost implications. Thus, 
identifying and evaluating populations at increased risk of developing osteoporosis is critical 
for disease prevention. Although osteoporosis traditionally has not been listed as a 
complication of diabetes, patients with either type 1 or type 2 diabetes mellitus are among those 
at increased risk for this disease (Chau & Edelman, 2002).  
 
Vertebral and hip fractures both substantially reduce quality of life, and although vertebral 
fractures are more common than hip fractures, hip fractures have the greatest health and 
economic impact.  High-income settings have health and social systems that facilitate long-
term care; sub-Saharan Africa does not. Thus, younger family members are likely to take 
responsibility for the care of older relatives, further affecting individuals of working age. To 
date, no studies have been published on the health costs of fractures within the SSA region. 
The predicted increase in fractures in SSA now means there is an urgent need to strengthen 
health-care systems (Gregson et al., 2019). 
 
The true occurrence of osteoporosis may be significantly underestimated because many women 
who suffer minimal trauma fractures are still not being evaluated for osteoporosis (Chau et al., 
2003).  Prevention of osteoporosis requires not only recognition of populations who are at risk, 
but also screening programmes targeting high risk populations. 
 
A review published by Wagner and Heyward (2000) examined the biological differences in 
body composition, including BMD between Blacks and Whites.  They stated that in general, 




Blacks have a greater BMD and whole-body protein content than Whites, resulting in a greater 
fat-free body density.  The purpose of this study was to determine the effect of T2DM on BMD 
in middle-aged black South African women. This approach agrees with the Surgeon General 
Bone Health and Osteoporosis Report (2004), which suggests that more research needs to be 




The aim of this study was to determine the impact of T2DM on the BMD of Black  




For the purpose of this study a DXA scan was done on all subjects participating in the study to 
determine the effect of T2DM on BMD in middle-aged Black South African women.  The 
participants were between the ages of 40 – 60 years.  The data of participants previously 
diagnosed with T2DM acted as the test group, and the data of volunteers not diagnosed with 
T2DM acted as the control group. 
 
To date, literature provide limited information about the effect of DM on the BMD of Black 
South African women. Therefore, it could be beneficial for the Black South African women 
population be investigated to address the shortage of information and to optimize treatment.  
 
 













The worldwide prevalence of diabetes has continued to increase dramatically and globally. As 
of 2011, an estimated 366 million people had diabetes mellitus (DM), with type 2 diabetes 
mellitus (T2DM) making up about 90% of all diabetes cases (Baynest, 2015).  The number of 
people with T2DM is on the rise in every country, with 80% of people with DM living in  
low- and middle-income countries. However, according to Baynest (2015), limited data are 
available on the prevalence of T2DM in Africa.  The studies that did investigate DM trends 
within Africa provide evidence of a dramatic increase in the prevalence of DM in both rural 
and urban settings, affecting both males and females proportionally (Kapoor et al., 2014; 
Ogbera & Ekpebegh, 2014).  According to Baynest et al. (2015), the prevalence of DM in 
Africa was (3.2%) and (2.0%) in Ethiopia. 
 
Osteoporosis is a common complication seen in patients suffering from DM - more specifically 
T2DM (Sundararaghavan et al., 2017). 
 
Bone fractures are the first symptoms of osteoporosis.  Osteoporosis is as a disorder with bone 
mineral density (BMD) 2.5 or more standard deviations (SD) less than the mean BMD in 
healthy young adults [T-score −2.5 or less] (WHO, 1994). The peak bone mass (PBM) of 




women is lower than that of men; therefore, as age advances, women are more likely to be at 
risk for osteoporosis.  It is estimated that every three seconds one osteoporotic fracture occurs 
somewhere in the world.  The universal burden of the low BMD almost doubled (0.12% vs. 
0.21%) over the 20–year period from 1990 to 2010, and low BMD caused nearly one-third of 
the all fall-related deaths around the world (Naz et al., 2016). 
 
2.2 Diabetes mellitus (DM) 
 
DM is a chronic metabolic disorder characterised by hyperglycemia that contributes to 
substantial morbidity and mortality.  Pharmacotherapy, continuing medical care and education 
are crucial for preventing acute and chronic complications of DM (Abdulameer et al., 2012). 
 
This also reflects an increase in associated risk factors, such as being overweight or morbidly 
obese. Over the past decade, diabetes prevalence has risen faster in low- and middle-income 
countries than in high-income countries.  In 2012 diabetes was the direct cause of 1.5 million 
deaths, and high blood glucose was the cause of another 2.2 million deaths worldwide (WHO, 
2016).  
 
According to the International Diabetes Federation (IDF) it was estimated that in 2017 there 
were 451 million (age 18–99 years) people with diabetes worldwide. These figures were 
expected to increase to 693 million by 2045. It was estimated that almost half of all people 
(49.7%) living with diabetes are undiagnosed (Cho et al., 2018).  
 
In 2006, the United Nations (UN) adopted a resolution on diabetes, urging member states to 
develop national policies for the prevention, treatment and care of diabetes. The designation of 
14 November as World Diabetes Day was also endorsed.  An African diabetes declaration, 
launched by the IDF held in Cape Town in 2006, aimed to raise community and political 
awareness of the disease (Butler, 2011).  




2.2.1  Types of diabetes mellitus 
 
The aetiological types of diabetes are classified as type 1 (T1DM), type 2 (T2DM), other 
specific types and gestational diabetes (Sundararaghavan et al., 2017).  Patients suffering from 
any type of DM may require insulin treatment at some stage.  The use of insulin by itself, does 
not allow for aetiological classification (Amod et al., 2012).   
 
T1DM results from pancreatic beta-cell destruction.  These patients are prone to ketoacidosis, 
coma and death.  Diabetes that is caused by an autoimmune process for which the aetiology of 
beta-cell destruction is unknown [which includes latent autoimmune diabetes in adults 
(LADA)] is also classified as T1DM (Amod et al., 2012).   
 
T2DM is the most common aetiological type and is predominated by disorders of insulin action 
(insulin resistance), and with insulin deficiency relative to a predominant secretory defect (i.e. 
disorders of insulin action and secretion).  The clinical distinction between T1DM and T2DM 
can sometimes be difficult, particularly in adolescents and young adults (Amod et al., 2012).  
 
Ndisang et al. (2015) mentioned in their article that in T1DM, autoimmune-mediated 
destruction of pancreatic beta-cells results in insulin deficiency. Obesity is one of the major 
causes of T2DM. In T2DM, a combination of peripheral insulin resistance and aberrant 
production of insulin are amongst the paradox commonly encountered in the pathogenesis of 
the disease. However, both forms of diabetes are characterised by elevated 
inflammation/oxidative stress, glucotoxicity, lipotoxicity, endoplasmic reticulum-induced 
stress with increased apoptosis and necrosis that ultimately leads to destruction loss of beta 
cells, and related complications including cardiomyopathy, nephropathy, neuropathy, and 
hepatopathy (Ndisang et al., 2015). 
 
 




2.2.2 Diagnosis of diabetes mellitus 
 
DM is diagnosed quite simply by measuring the level of glucose in the blood.   According to 
the 2017 Society for Endocrinology Metabolism and Diabetes of South Africa (SEMDSA) 
guidelines, the criteria for diagnosis is confirmed in patients with symptoms of hyperglycaemia 
(polyuria, polydipsia, blurred vision, weight loss) or metabolic decompensation (diabetic 
ketoacidosis or hyperosmolar non-ketotic state), when any one single test confirms that the:  
 
i. Random plasma glucose is ≥ 11.1 millimoles per litre (mmol/L)  
ii. Fasting plasma glucose is ≥ 7.0 mmol/L  
iii. Haemoglobin A1c (HbA1c) is ≥ 6.5% ◦ 2-hour post-load glucose is ≥ 11.1 mmol/L.  
However, a GTT is rarely needed in this category of patient.  
 
In an asymptomatic individual, when any one of the following tests, repeated on separate days 
within a 2-week period confirms that the:  
 
i. Fasting plasma glucose is ≥ 7.0 mmol/L  
ii. 2 hr-post load oral glucose tolerance test (OGTT) is ≥ 11.1 mmol/L  
iii. HbA1c is ≥ 6.5%  
 
If the diagnosis of diabetes is not confirmed with the repeated test, institute lifestyle 
modification and retest in 3 to 6 months is needed (Amod et al., 2017). 
 
 









Table 2.1:  Clinical differences between T1DM and T2DM (adapted from Amod et al.,   







Usually < 30, but not always 
Usually older, but prevalence in children, adolescents and young adults 
increasing 
Usually lean weight Mostly overweight or obese with acanthosis nigricans 
Onset is acute Onset is insidious/gradual 
Almost always symptomatic (i.e., polyuria, 
polydipsia, weight loss) 
Often asymptomatic 
Prone to ketosis, often ketoacidosis at 
diagnosis 
Not usually prone to ketosis, but ketoacidosis may be present at diagnosis 
Diagnosis:  usually has unequivocal 
hyperglycemia 
Diagnosis often during routine screening 
Insulin necessary, as of diagnosis, for 
survival 
Usually controlled with non-insulin therapies, or may need insulin for 
symptom control 
Otherwise normally healthy 
Often have co-morbidities e.g., hypertension, dyslipidemia, sleep apnoea, 
fatty liver disease, and polycystic ovary syndrome or diagnosed after 
emergency admission for myocardial infarction or stroke  
 
 
The study was conducted on T2DM volunteers. 
 
 
2.3 Type 2 diabetes mellitus (T2DM) 
2.3.1 The pathophysiology of T2DM 
 
According to Khan et al. (2014) normal regulation of glucose metabolism is determined by a 
feedback loop involving the islet β-cell and insulin-sensitive tissues in which tissue sensitivity 
to insulin determines the magnitude of the β-cell response. When insulin resistance is present, 
the β-cell maintains normal glucose tolerance by increasing insulin output.  It is only when the 
β-cell is incapable of releasing sufficient insulin in the presence of insulin resistance that 
glucose levels rise. While β-cell dysfunction has a clear genetic component, environmental 
changes play a vital role. Modern approaches have also informed regarding the importance of 




hexoses, amino acids and fatty acids in determining insulin resistance and β-cell dysfunction 
as well as the potential role of alterations in the microbiome.  Khan et al. (2014) explained that 
like most endocrine systems, a feedback loop operates to ensure integration of glucose 
homeostasis and maintenance of glucose in a tight range.  This feedback loop relies on crosstalk 
between the β-cell and the insulin sensitive tissues (Figure 2.1 A). Insulin released in response 
to β-cell stimulation mediates the uptake of glucose, amino acids and fatty acids by insulin-
sensitive tissues. In turn, these tissues feedback information to the islet regarding their need for 
insulin, the mediator of which has not yet been identified but is likely to involve integration 
between the brain and humoral systems. When insulin resistance is present, as seen most 
commonly with obesity, the β-cell increases its insulin output to maintain normal glucose 
tolerance (Figure 2.1 B). However, when the β-cell is incapable of this task, the result is an 
elevation in plasma glucose (Figure 2.1 C) (Khan et al., 2014). 
 
                       A                                                    B                                                      C 
 
Figure 2.1: Feedback loop between the islet β-cell and the insulin-sensitive tissues 
  (A) Insulin acts in the liver to suppress glucose production, and in the muscle 
  and adipose tissue to stimulate the uptake of glucose, amino acids and fatty 
  acids.  The amount of insulin released to maintain normal glucose homeostasis 
  is determined by the prevailing insulin sensitivity. This feedback is likely 
  mediated through neuronal and humoral mechanisms, but the exact mediators 
  are still not known. (B) When insulin resistance develops in the insulin- 
  sensitive tissues, feedback to the β-cell ensures that it increases insulin output 




  to maintain normal glucose tolerance. (C) When the β-cell is incapable of  
  increasing insulin output in the presence of insulin resistance, the result is the 
  development of elevated glucose levels, initially manifest as impaired glucose 
  tolerance. As β-cell dysfunction progresses, further elevations in glycaemia 
  occur and diabetes is the eventual result (Adapted from Khan et al., 2014).  
 
In addition to a considerable number of genetic components associated with T2DM, 
segregation analysis also suggests the polygenic nature of T2DM.   Most identified diabetes 
loci have not been mechanistically tied to the disease. While loci are commonly referred to by 
the names of genes located close to them, only a few are close to strong biological candidates, 
e.g., the melatonin receptor 1B (MTNR1B) and the insulin receptor substrate-1 (IRS-1). For 
others, like Transcription factor 7-like 2 (TCF7L2) and Gastric Inhibitory Polypeptide 
Receptor (GIPR), the evidence is quite strong that an intronic single polymorphisms (SNP) is 
the causal SNP (Prasad & Groop, 2015). MTNR1B has been associated with both fasting 
glucose and T2DM risk.  Melatonin works as a chronobiotic factor, adjusting the timing of the 
biological clock.  Its receptors are present in the pancreas and melatonin is proposed to 
contribute to the nocturnal lowering of insulin in humans. The MTNR1B risk genotype is 
associated with impaired early insulin release to both oral and intravenous glucose and insulin 
secretion deteriorates over time in the risk allele carriers.  The proposed mechanism by which 
MTNR1B polymorphism could predispose to T2DM involves altered expression of MTNR1B 
in pancreatic β-cells, leading to decreased cyclic adenosine monophosphate /cyclic guanosine 
monophosphate (cAMP/cGMP) concentrations via G proteins and, thereby, impaired insulin 
secretion (Cöl et al., 2018; Prasad & Groop, 2015). 
 
Like Prasad and Groop (2015), Dendup et al. (2018) also suggest a link between the 
environment and health outcomes closely related to T2DM such as obesity, cardiovascular 
diseases, hypertension, metabolic syndrome and physical activity.  Obesity contributes to an 
increased production of glucose by the liver.  This leads to a “prediabetes” condition, wherein 
the glucose levels are high but under the T2DM range. The metabolism of carbohydrate, fat, 




and protein is disturbed as the disease progresses.  Hyperglycemia (high blood sugar levels) 
results when the β-cells fail to compensate insulin resistance with excess insulin output.  The 
progressive decline of the β-cell function and mass over time with hyperglycemia marks the 
development of T2DM.  Accumulation of fat in the liver, muscles, and pancreas from surplus 
calories and physical inactivity contributes to β-cell dysfunction and insulin resistance.  
Inflammation, oxidative and endoplasmic-reticulum stress, raised lipid levels, and amyloid 
accumulation also trigger β-cell dysfunction.  Gastrointestinal tract hormones and the nervous 
system, including the brain, also act on β-cells and glucose metabolism.  Early diagnosis and 
treatment with lifestyle interventions (physical activity, diet, and weight loss) and glucose-
lowering medications can reduce complications and vascular diseases and prevent or delay 
disease progression. However, in type 2 diabetes of duration greater than 10 years, the cellular 
changes appear to pass a point of no return. This review summarizes the evidence that early 
type 2 diabetes can be regarded as a reversible β-cell response to chronic positive calorie 
balance. (Dendup et al. 2018; White et al., 2016). 
 
Lifestyle factors contributing to the development of T2DM, include a sedentary lifestyle, 
physical inactivity, smoking and alcohol consumption.  As mentioned previously, obesity is 
the most important risk factor for T2DM, which may influence the development of insulin 
resistance and disease progression.  Nearly 90% of diabetic patients develop T2DM mostly 
relating to excess body weight (Ley et al., 2016).  Furthermore, obesity is strongly inherited.   
 
In addition, Wu et al. (2014), stated that diet is considered as a modifiable risk factor for T2DM.  
They mentioned that a low-fiber diet with a high glycemic index is positively associated with 
a higher risk of T2DM, and they found that specific dietary fatty acids may affect insulin 
resistance and the risk of diabetes in varying degrees.  Total and saturated fat intake is 
associated with an increased risk of T2DM independently of body mass index (BMI), but 
higher intake of linoleic acid has the opposite effect, especially among leaner and younger men. 
Frequent consumption of processed meat, but not other meats, may increase the risk of T2DM 
after adjustment for BMI, prior weight change, and alcohol and energy intake. Soft drinks have 




also been bounded up with increased risk of T2DM and metabolic syndrome, because they are 
directly associated with BMI (Wu et al., 2014). 
 
2.3.2 Complications associated with T2DM  
 
The complications of DM can be divided into acute and chronic complications.  Acute 
complications include diabetic ketoacidosis, hyperosmolar hyperglycemic nonketotic coma, 
Somogyi effect, Dawn phenomenon and hypoglycemia.  Long-term complications can include 
cardiovascular complications both micro- and macrovascular, vision loss (retinopathy), renal 
damage, peripheral nervous system damage, autonomic neuropathy and metabolic syndrome 
(Chawla et al., 2016). 
 
Despite the complications mentioned above, patients with DM can also sustain secondary 
complications and have an increased risk of falling because of primary complications like 
peripheral neuropathy, possible hypoglycemia, nocturia, and visual impairment. Because many 
T2DM patients are obese and sedentary, coordination and balance factors acting as protective 
mechanisms against falls may be absent (Chau & Edelman, 2002).  
 
 
2.3.2.1 Factors contributing to falls in DM patients  
 
a) Vision related 
 
• Diabetes retinopathy 
• Advanced cataracts (visual field deficits) 
• Laser therapy for retinopathy (peripheral and night vision decreases) 
• Hypoglycemia 




b) Gait/balance related 
 
i. Peripheral 
ii. Foot ulcers 
iii. Polyuria and nocturia, urgent and frequent trips to the restroom, especially at night 
iv. Decreased reflexes 
 
Another important complication associated with DM is low bone mass, thus contributing to 
osteoporosis (Abdulameer et al., 2012).  For the purpose of this study emphasis was placed on 
osteoporosis as a complication of T2DM. 
 
2.3.3 Potential mechanisms contributing to low bone mass in T2DM  
 
Lifestyle choices influence 20 – 40% of adult PBM (Weaver et al., 2016). Therefore, 
optimisation of lifestyle factors known to influence PBM and strength is an important strategy 
aimed at reducing risk of osteoporosis or low bone mass later in life.  
 
The ability of bone to resist fracture depends on several factors including bone mass, the 
shape and microarchitecture of the bone, and innate properties of the materials that comprise 
the bone (e.g., mineralisation and microdamage).  Bone density measures grams of mineral 
per area or volume and is determined by PBM and the amount of bone loss.  PBM is achieved 
between the ages of 18 and 25 years and is largely determined by genetic factors.  Other 
determinants of PBM include nutrition, endocrine status, physical activity, and overall health 
during growth (Dempster, 2011).  
 
Bone mass in older adults equals the PBM achieved by age 18–25 years minus the amount 
of bone subsequently lost due to menopause when remodeling becomes unbalanced and rapid. 
Each of the many remodeling transactions deposits less bone than it resorbed, producing 




microstructural deterioration (Bjornerem et al., 2017).  PBM is determined largely by genetic 
factors, with contributions from nutrition, endocrine status, physical activity, and health 
during growth.  The process of bone remodeling that maintains a healthy skeleton may be 
considered a preventive maintenance programme, continually removing older bone and 
replacing it with new bone. Bone loss occurs when this balance is altered, resulting in greater 
bone removal than replacement. The imbalance occurs with menopause and advanced age. 
With the onset of menopause, the rate of bone remodeling increases, magnifying the impact 
of the remodeling imbalance. The loss of bone tissue leads to disordered skeletal architecture 
and an increase in fracture risk (Cosman et al., 2014).             
 
High glucose levels in T2DM leads to the accumulation of advanced glycosylation end-
products (AGEs) in the organic bone matrix by a process known as non-enzymatic glycation 
(the Maillard reaction) (Singh et al., 2014).  Increased AGEs may weaken bone by decreasing 
bone formation. There is evidence suggesting that AGEs interfere with normal osteoblast 
development, function and attachment to the collagen matrix.  Moreover, low bone formation 
also works in the opposite direction to further increase AGEs, as, for example, with high 
bisphosphonate dosages. Biochemical markers of bone formation have generally been reduced, 
although T2DM has not definitely been established to contribute to low bone formation (Leslie 
et al., 2012). 
 
In contrast to T1DM with autoimmune ß-cell destruction and complete insulin and amylin 
deficiency, T2DM is characterised by peripheral insulin resistance with a variable degree of 
hyperinsulinemia and impaired insulin secretion after a metabolic challenge by glucose.  
Hyperglycemia may have several adverse effects on bone metabolism both in patients with 
poorly controlled T1DM and T2DM. Glucose is the principal energy source for osteoclasts and 
is able to dose-dependently enhance avian osteoclast activity in vitro. In addition, 
hyperglycemia leads to non-enzymatic glycosylation of various bone proteins, including type 
I collagen, which may impair bone quality (Hofbauer et al., 2007). Figure 2.2 represents a 
suggested model of potential deleterious effects of diabetes on bone based on in vitro findings, 
animal studies, and observational human data. 

















Figure 2.2: Potential mechanisms contributing to low bone mass and increased 
fracture susceptibility in DM (adapted from Hofbauer et al., 2007). 
 
Currently, it can be concluded that T2DM compromises bone microstructure by inducing 
aberrant bone cell function (cellular failure) and abnormal matrix structure (matrix failure). 
Regarding the cellular effect, T2DM is associated with increased osteoblast apoptosis, 
diminished osteoblast differentiation, and enhanced osteoclast-mediated bone resorption, 
which, in part, resulted from hyperglycemia and insulin resistance. Prolonged accumulation of 
AGEs coexisting with a decrease in lysyl oxidase activity causes abnormal structure and 
alignment of collagen, leading to bone fragility. Several confounding factors in T2DM, 
particularly body weight gain, obesity, and dyslipidemia, can mask the detrimental effects of 
T2DM, and may delay diagnosis of diabetic osteoporosis. In other words, bone is already 








2.4 What is osteoporosis?   
 
Osteoporosis is the most common metabolic bone disorder in humans, and bone fractures are 
the hallmark of the disease. It constitutes an enormous socio-economic crisis with severe 
impact on patient morbidity and mortality (Abdulameer et al., 2012). The disease is 
characterised by low bone mass, deterioration of bone tissue and disruption of bone 
architecture, compromised bone strength, and an increase in the risk of fractures (Siris et al., 
2014). 
 
It can be caused by acceleration of bone resorption and/or deceleration of bone formation. 
Clinically, osteoporosis most often results from a combination of postmenopausal estrogen 
deficiency and age-related bone loss. Irreversible bone loss can result from an imbalance 
between osteoclast and osteoblast activities, i.e. enhanced bone resorption and/or suppressed 
bone formation, resulting in an uncoupling event that can prolong duration of the bone 
remodeling cycle (Wongdee & Charoenphandhu, 2011). 
 
Although often thought of as a static support structure, the skeletal system is a dynamic organ 
with many functions, including giving us our human shape, allowing locomotion and motor 
function, facilitating respiration, protecting vital organs, producing marrow-derived cells, and 
playing a crucial role in homeostasis (Hossain, 2018).  Bones are dynamic structures that are 
undergoing constant change and remodeling in response to the ever-changing environment. 
The human skeleton is completely transformed every four years. Bones can react and respond 
to environmental stimuli; they can become bigger or smaller, they can strengthen themselves 
when need be, and, when broken, they are among the few organs in the body with the ability 
to regenerate without scarring (Petre et al., 2013). 
 
Bone must be stiff and able to resist deformation, therefore allowing loading capacity, but also 
be flexible and able to deform to allow energy absorption during impact loading. Bone must 




also be light to allow movement. The balance between bone’s material stiffness and its 
flexibility is achieved by varying its mineral content. The greater the mineral content, the 
greater the material stiffness and the lower the flexibility. Bone strength, one of its major 
determinants, is dependent both on bone mass, reflected by BMD, and on bone 
microarchitecture (Jackuliak & Payer, 2014). 
 
The changes within cancellous bone as a result of bone loss is illustrated in Figure 2.3. 
Individual trabecular plates of bone are lost, leaving an architecturally weakened structure 
with significantly reduced mass. Increasing evidence suggests that rapid bone remodeling (as 
measured by biochemical markers of bone resorption or formation) increases bone fragility 





Figure 2.3:  The changes within cancellous bone as a results of bone loss (adapted from  
                    Cosman et al., 2014) 
 
The main recognised functions of bone remodeling include preservation of bone mechanical 
strength by replacing older, micro-damaged bone with newer, healthier bone and calcium and 
phosphate homeostasis. Both cortical and trabecular bone are composed of osteons. The 
relatively low adult cortical bone turnover rate of 2 to 3% per year is adequate to maintain 
biomechanical strength of bone. The rate of trabecular bone turnover is higher, more than 




required for maintenance of mechanical strength, indicating that trabecular bone turnover is 
more important for mineral metabolism (Clarke, 2008).  
 
Most bones have a thick, well-organised outer shell (cortex) and a less dense mesh of bony 
struts in the center (trabecular bone) (Figure 2.4). The ratio of cortical bone to trabecular bone 
varies widely; in adults, this ratio is typically 80:20.  The only bones that lack a true cortex are 
the vertebrae, which are covered by a compact condensation of trabecular bone (Spencer et al., 
2015).  According to Clarke (2008) the vertebra is composed of cortical to trabecular bone in 
a ratio of 25:75, whilst the ratio is 50:50 in the femoral head. Trabecular bone is found on the 
interior of cortical bone and is less dense.  Cortical bone is the dense, extremely strong bone 
that is found at the periphery of bones.  It makes up 80% of the skeleton.  Its primary function 
is mechanical, but it has a role in calcium homeostasis as well. Mature cortical bone is lamellar, 
meaning it has a distinct layered structure (Figure 2.5) (Petre et al., 2013). 
 
 
Figure 2.4:  Trabecular and cortical bone (adapted from Petre et al., 2013) 
 
 





Figure 2.5:  Anatomy of bone (adapted from Petre et al., 2013) 
 
2.5 Osteoporosis and peak bone mass (PBM) 
 
PBM in young adults is a major determinant of bone mass later in life.  Environmental 
influences such as exercise, smoking, and nutrition, as well as genetic influences are mediated 
in part by hormonal regulation of bone accrual during growth and maturation. The major and 
most extensively studied hormonal systems implicated in this regulation are the somatotropic 
and the gonadal axes. Another hormonal determinant of PBM is thyroid hormone, known to 
have potentially marked effects on bone maturation and metabolism (Roef et al., 2011).    
 
Wilken et al. (2010) stated that although research varies on the age at which peak BMD is 
reached, most suggest that peak BMD is reached somewhere between the ages of 20 and 30 
years. These authors also mentioned that some investigators suggest that 95% of peak BMD 
is reached by age 17 years for females and two to three years later for males, while others 
suggest PBM is reached by age 30 years for most bone sites.  It has been further suggested 
that osteoporosis is a pediatric disorder that manifests in old age.  Furthermore, females can 
lose up to 20 percent of their bone mass in the five to seven years following menopause, 
making them more susceptible to osteoporosis (Wilken et al., 2010).   




2.6 Relationship between T2DM and osteoporosis 
 
Though the relationship between T2DM and osteoporosis has been widely investigated, it 
remains controversial. 
 
Patients with DM have various skeletal disorders, including osteopenia or osteoporosis, 
Charcot’s arthropathy, and diabetic foot syndrome. According to Hofbauer et al. (2007), bone 
and mineral abnormalities in patients with DM may be caused by:  
 
• direct effects of insulin deficiency or resistance and hyperglycemia on the bone and 
bone marrow micro-environment, 
• AGEs of bone matrix proteins, abnormal cytokine and adipokine production and their 
detrimental effects on bone cells, and  
• impaired neuromuscular/skeletal interactions.  
 
Furthermore, several other diabetic mechanisms could influence bone, some of which may 
have contradictory effects. Obesity is strongly associated with higher BMD, probably through 
mechanical loading and hormonal factors, including insulin, estrogen, and leptin.  Low levels 
of insulin and the progression of T2DM may cause reductions in BMD. Higher glucose levels 
in the blood are known to interact with several proteins to generate a higher concentration of 
AGEs in collagen that may reduce bone strength. Accumulated AGEs in the body may 
stimulate apoptosis of osteoblasts, thereby contributing to deficient bone formation. Another 
indirect effect of hyperglycemia is glycosuria, which causes hypercalciuria, leading to 
decreased levels of calcium in the body and poor bone quality, hastening bone loss.  There is 
established evidence that low levels of vitamin D are not only associated with the incidence of 
DM but also that altered vitamin D metabolism leads to diabetic osteopenia (Abdulameer et 
al., 2012). 
 




DM contributes to the development of osteoporosis because DM leads to reduced metabolic 
activity of osteoblasts, increased osteoclastic activity due to diabetic acidosis, secondary 
hyperparathyroidism related to diabetic nephropathy, reduced sexual hormones secretion, 
increased secretion of glycocorticoids, and decreased blood supply to bones due to diabetic 
angiopathy (Al-Maatouq et al., 2004).  
 
Diabetes itself is associated with increased risk of bone fractures, although T2DM is often 
characterised by normal or high BMD. Thus, diabetes may be associated with a reduction of 
bone strength that is not reflected in the measurement of BMD.  Diabetic osteopathy is a 
significant comorbidity of both forms of diabetes and is characterized by micro-architectural 
changes that decrease bone quality, leading to an increased risk of bone fractures in both types 
of diabetes.  In T2DM, obesity, increased load on bone, and insulin resistance resulting in 
hyperinsulinemia contribute to increased bone formation (Jackuliak and Payer, 2014). 
Furthermore, bone loss has been observed to be greater in patients with poorly controlled 
diabetes than in those patients with well-controlled diabetes (Chau & Edelman, 2002).  
 
Shan et al. (2011) studied 1 253 women with T2DM and 1 194 control subjects aged 40-80 
years in mainland China.  They investigated age-related BMD, bone projective area (BPA) and 
the prevalence of osteoporosis using DXA.  These authors reported that the BMD of the lumbar 
spine and hip decreased with age. BMD of the lumbar spine was higher in T2DM patients than 
in the control subjects. The same was observed for BPA at some vertebral bodies, whereas no 
significant intergroup differences in BPA were observed at the hip. The prevalence of 
osteoporosis in the women with T2DM increased with age: 0.00-2.58% at age 40-49 e years; 
6.94-28.40% at age 50-59 years, 32.70-76.70% at age 70-80 years, with the range reflecting 
differences between skeletal sites. In patients over 60 years, the rates of osteoporosis at the 
anteroposterior (AP) spine were significantly lower in T2DM patients than in the control 
subjects. They concluded that women with T2DM had higher BMD and a lower risk of 
developing osteoporosis compared to non-diabetic patients. 
 




Al-Maatouq et al. (2004) studied the prevalence of osteopenia and osteoporosis among Saudi 
postmenopausal women with non-insulin dependent T2DM.  BMD of the lumbar spine and 
femoral neck using DXA was performed on 104 postmenopausal Saudi women with T2DM, 
and 101 postmenopausal non-diabetic women (control).  They concluded that osteoporosis is 
more common among T2DM postmenopausal females in this ethnic group. Since both groups 
are postmenopausal, having equal percentage of Vitamin D deficiency, multi-parity, non-
exposure to sun, lack of exercise and negligible milk intake, one can conclude that the low 
BMD can be attributed to DM in the absence of other causes of osteoporosis (Al-Maatouq et 
al., 2004). 
 
The American Iowa Women’s Health Study (Anderson et al., 2001) reported that women with 
T2DM had a 1.7-fold higher risk for reporting hip fractures compared with women without 
T2DM.  It has been suggested that long-standing T2DM may predispose to a higher incidence 
of falls, thus increasing the likelihood of suffering fractures despite higher average BMD values 
reported in these patients (Hofbauer et al., 2007).  
 
2.7 Factors contributing to the risk of developing osteoporotic fractures 
2.7.1 Gender and ethnicity associated with osteoporosis 
 
There are several risk factors that increase the risk for fracture development, which include 
BMD, bone geometry, age, fall rates, fracture history, and medication used, to name but a few 
(Pisani et al., 2013). 
 
Cauley (2011) stated that gender and ethnicity is strong determinants of fracture risk. In 
general, White women experience hip fractures about twice as much as men, especially in 
countries with high incidence rates, but the gender difference in hip fracture risk in African 
Americans and Asians is negligible.  Spencer et al. (2015) mentioned that clinical studies 




suggest bone also varies due to ethnicity or ancestry. He claims that it has been shown that 
people of African descent have higher BMD than Caucasians (Pollitzer & Anderson, 1989; 
Wang et al., 1997; Ortiz et al., 1992) and people of Hispanic origin have BMD similar to 
Caucasians, with Asians having lower bone mass than Caucasians (Pollitzer and Anderson, 
1989; Barrett-Connor et al., 2005; Cundy et al., 1995).  Rates of hip fractures are about 50% 
lower in African American and Asian women than in White women. Ethnic and race variability 
is much lower for men, although White men tend to have slightly higher hip fracture rates 
compared to Asian and African American men (Cauley, 2011).  BMD is consistently higher in 
African American women than in White women at every level of body weight and could 
contribute to their lower fracture rates (Cauley, 2011). However, differences in hip geometry 
could also contribute.  Longer hip axis lengths have been linked to an increased risk of hip 
fractures, and hip axis lengths are reportedly shorter among African Americans and Asians, 
even after adjusting for height.   
 
The amount of bone mass a person has, along with bone structure, varies between individuals 
and populations due to ethnicity, sex, age, diet, or even behavior.  According to Spencer et al. 
(2015), people of African descent have greater bone mass than Caucasians.    
 
There are substantial geographic and ethnic variations in fracture rates around the world. For 
both men and women, the highest age-adjusted hip fracture rates have been reported in North 
Europe and America, and the lowest rates in Africa. Caucasians have the highest rates of hip 
fracture compared to other ethnic groups.  It is believed that the higher the BMD, the lower the 
risk for bone fractures (Chan et al., 2018). Differences exist in the areal BMD between ethnic 
and racial groups and gender.  Areal BMD integrates the size of the bone with its thickness and 
true volumetric density, while areal BMD is similar in White and Asian patients. Asians 
reportedly have higher trabecular volumetric BMD, at least in older men, which could 
contribute to their lower fracture rates (Cauley, 2011).   
 
Ma et al. (2012) provide insights into the inconsistent reported relationship between T2DM 
and BMD. Their meta-analysis concluded that overall individuals with T2DM have 




approximately a 25–50% higher BMD SD compared to non-diabetic control subjects.  Subjects 
with T2DM had elevated BMD at the femoral neck, hip, and spine.  They reported no evidence 
suggesting there is gender-specificity in the observed BMD differences between diabetics and 
non-diabetics.  BMD differences seem larger in women than in men, but according to Ma et al. 




Insulin is an anabolic hormone, which acts on bone through insulin receptors expressed by 
osteoblasts— IRS-1 and insulin receptor substrate 2 (IRS-2) (insulin-like substrate). 
Stimulation of IRS-1 affects bone turnover, while stimulation of  IRS-2 shifts the balance 
between bone formation and resorption towards the former. Insulin stimulates osteoblast 
proliferation, inactivates p27 (responsible for osteoblastogenesis), promotes collagen 
synthesis, and increases glucose uptake (Li et al., 2016).  In T1DM, the deficiency of insulin 
and insulin growth factor 1 (IGF-1), which is present since the diagnosis of T1DM, leads to 
impaired bone formation, abnormal mineralisation, abnormal bone micro-architecture, 
increased fragility of the bone, and reduced PBM. In T2DM hyperinsulinism (the stimulatory 
effects of insulin on bone formation) coupled with insulin resistance increase bone mass 
through effects on bone formation via IRS-1 and IRS-2 surface receptors on osteoblasts, and 
by reducing the concentration of sex-hormone binding globulin (SHBG), which leads to 













Nutrition is an important component of bone health.  The value of nutrients such as calcium is 
well documented. Protein makes about 50% of bone volume and approximately one-third of 
its mass.  It provides the structural matrix of bone, whereas calcium is the dominant mineral 
within that matrix. Collagen and a variety of non-collagenous proteins form the organic matrix 
of bone, so an adequate dietary protein intake would seem to be essential for optimal acquisition 
and maintenance of adult bone mass (Shams-White et al., 2017).  Previously dietary protein 
intake has been implicated in the loss of bone due to the acidification of blood.  Wolfe (2015) 
indicates that, when net bone formation has been determined, higher rates of protein intake 
have been shown to have beneficial effects on bone health.  He mentioned that bone strength 
is directly affected by the torque placed on the bones because of muscular contraction.  Because 
higher levels of protein intake increase strength in the elderly, increased protein intake may 
have an indirect effect on bone strength by enabling the generation of greater muscular force 
(Wolfe, 2015). 
 
2.7.4 Vitamin D 
 
Maintaining adequate calcium intake during childhood and adolescence is necessary for the 
attainment of PBM, which may be important in reducing the risk of fractures and osteoporosis 
later in life.  Approximately 99% of total body calcium is found in the skeleton, with only small 
amounts found in the plasma and extravascular fluid. The primary need for dietary calcium is 
for bone mineral deposition.  Calcium and vitamin D can decrease postmenopausal bone loss 
and prevent fracture risk. However, there is still a high prevalence of calcium and vitamin D 
insufficiency in women aged 50+ years. Dietary sources of these nutrients are the preferred 
choice, and dairy products represent a valuable dietary source of calcium due to the high 




content, high absorptive rate and relatively low cost (Rizolli et al., 2014).  Overall calcium 
homeostasis is maintained by the actions of calcium-regulating hormones, which most notably 
include parathyroid hormone, calcitonin, and 1, 25-dihydroxy vitamin D. Calcium is absorbed 
in the intestine by both passive and active processes, the active process being more important 
in situations in which dietary calcium intakes are suboptimal. The active process requires 
vitamin D, which emphasises the fact that good bone health requires satisfactory intakes of 
both calcium and vitamin D. Optimising calcium intake is particularly important during 
adolescence. Peak calcium-accretion rate is attained at an average of 12.5 years of age in girls, 
and at 14.0 years of age in boys.  During the third to fourth year period of increased bone mass 
acquisition that occurs during adolescence, 40% of total lifetime bone mass is accumulated.  
This emphasises the importance of establishing dietary practices in childhood that promote 
adequate calcium intake throughout life (Greer et al., 2006).  
 
Most studies across a variety of geographic locations suggest that vitamin D insufficiency is 
more common in individuals with diabetes compared to the general population. Proposed 
mechanisms for vitamin D deficiency in diabetes include genetic predisposition (T1DM), 
increased BMI (T2DM), concurrent albuminuria (T1DM or T2DM), or exaggerated renal 
excretion of vitamin D metabolites or vitamin D-binding protein (T1DM, T2DM) (Jackuliak 
& Payer, 2014). 
 
Gilani et al. (2019) have done a study on 69 females and 40 males. The mean age was 44.13 
years. Their study showed a statistically significant difference in the vitamin D status in 
diabetic versus non diabetic patients. With regards to BMI and vitamin D status, the difference 
was also statistically significant. Caglar et al. (2017) demonstrated a negative correlation 
between Vit D and BMI when they studied 31 Turkish women with BMI>25 kg/m2. It seems 









2.7.5 Barriers to adequate calcium intake 
 
Mangano et al. (2014) suggest that dietary protein is beneficial to bones, and this may be most 
apparent when calcium intake is optimal.  He mentioned that a higher protein diet increases 
IGF-1 (a key mediator of bone health), increases intestinal calcium absorption, suppresses 
parathyroid hormone, and improves muscle strength and mass, all of which may benefit the 
skeleton.     
 
Vitamin D is another essential component for bone health. In addition to adequate calcium 
intake, maintaining an optimal vitamin D level is necessary for preventing bone loss (Kim et 
al., 2014).  Suboptimal intakes of calcium in children and adolescents may be related to the 
replacement of milk intake by soft drinks and fruit juices and/or other fruit drinks.  Soft-drink 
consumption peaks in adolescence, at which time milk intake is at its lowest level (Larson et 
al., 2015).  Primary lactose intolerance may be a problem in some populations. It is more 
common in children of African, Mexican, American Indian, and Asian descent than in White 
children (Deng et al., 2015).  Many children with lactose intolerance can drink small amounts 
of milk without discomfort, especially when accompanied by other foods. Intolerance to the 
consumption of 250 millileter (ml) of milk or less is rarely seen in preadolescents, and the 
addition of small amounts of lactose-containing foods to the diet may decrease the severity of 
lactose intolerance (Greer et al., 2006).  Other alternatives include the use of fermented dairy 
products such as hard cheese and yogurt, which may be tolerated better than milk. Lactose-free 
and low-lactose milks are available. Non-dairy food products (such as certain vegetables) or  
calcium-supplemented foods (including calcium-fortified soy milk) may be used as other 
calcium sources, especially for vegetarians who do not consume dairy products (Greer et al., 
2006).  Deng et al. (2015) suggested that treatment of lactose intolerance should not be 
primarily aimed at reducing malabsorption, but rather at improving gastrointestinal symptoms.  
In their experience, this approach is effective if symptoms are related only to dairy products; 
however, in irritable bowel syndrome (IBS) patients, lactose intolerance tends to be part of a 




wider intolerance to poorly absorbed, fermentable oligo-, di-, monosaccharides and polyols 
(FODMAPs).   
 
According to Kim et al. (2014) low dietary calcium intake is associated with low bone density, 
and calcium supplementation can attenuate age-related bone loss.  Therefore, they suggested 
that calcium supplementation is generally recommended for people who might be at risk of 
inadequate dietary calcium intake or osteoporosis, regardless of age, particularly to prevent 
deterioration in bone strength in postmenopausal women. 
 
2.7.6 Weight-bearing exercise 
 
Shanb and Youssef (2014) state that exercise training has many advantages such as improving 
mechanical properties of bone by changing its composition.  They suggest that public health 
programmes should be designed to help prevent bone loss and promote osteogenesis, improve 
body composition, muscle strength and balance, and reduce recurrent falls and associated risks 
of fractures. 
 
According to Greer et al. (2006), weight-bearing exercise also plays a role in achieving 
maximal PBM, but data to quantify the effect are limited. These authors indicate that there is 
evidence that childhood and adolescence may represent an important period for achieving  
long-lasting skeletal benefits from regular exercise. For example, regular weight-bearing 
activity had a greater influence on PBM than did dietary calcium intake in children. It is still 
unclear whether a given level of calcium intake influences the degree of benefit derived from 
physical activity on bone mass, or whether exercise alone, independent of calcium intake, 
improves bone mass.  According to Greer et al. (2006) further studies needs to explore the 
combined effects of calcium and exercise on bone mass.  
 




Different exercise techniques that benefit mechanical properties of bone are recommended.   
Some are resistive exercises in the form of strength training programmes, which are used to 
increase muscular strength, enhance bone mass, improve balance and mobility, and in turn lead 
to improved quality of life.  There are also weight-bearing exercises which are most popular 
with children, adolescents, adults, and postmenopausal women, because these exercises 
generate the highest mechanical load on bones. Weight-bearing exercises are applied with 
different modes such as walking, running or jumping (Shanb & Youssef, 2014). 
 
2.7.7 Muscle strength and bone mass 
 
Chahal et al. (2014) explain that mechanical loading from physical activity is a key determinant 
of the growth and maintenance of the musculoskeletal system.  They describe how bone and 
muscle can increase their mass and strength rapidly in response to mechanical loading during 
the early years through the process of modelling.  Peak mass and strength are usually attained 
around the second and third decade.  However, with the ageing process, there is a decline in 
musculoskeletal health in both men and women. The primary musculoskeletal changes reported 
with ageing include a decline in skeletal muscle mass, strength and size, together with a net 
loss of BMD, bone mineral content (BMC), bone structure and strength (Chahal et al., 2014). 
 
Physical activity increases muscle strength and bone mass, while disuse causes muscle wasting 
and bone loss.  Neither body weight nor physical activity is independent of muscle mass, but 
muscle forces place greater loads on bones than do gravitational forces associated with weight 
(Burr, 1997).   The mechanostat propose that bone gain and loss are determined within ranges 
of mechanical stimulation that are bounded by hormonal or metabolically determined set 
points.  The set points do not themselves determine whether bone will be gained or lost, only 
when the remodeling system will be activated above baseline levels or inactivated. Mechanical 
usage modulates an activated remodeling system and determines bone balance (Burr, 1997).   




Pivonka et al. (2018) explain the conceptual model of the mechanostat proposed by Harold 
Frost in 1983. This model states that bone and other musculoskeletal tissues, including 
cartilage, tendon and muscle, respond to habitual exercise/loading, and that changes in the 
loading environment lead to adequate structural adaptation of (bone) tissue architecture. The 
analogy with a thermostat clearly indicates the presence of a physiological feedback system 
which can adjust bone mass and structure according to the engendered loads.  Pivonka et al. 
(2018) recognise that in the bio-engineering community, the mechanostat has been 
mathematically formulated as a feedback algorithm using a set point criterion based on a 
particular mechanical quantity such as strain - strain energy density, among others.  The belief 
that a single mechanostat set point exists in an individual is flawed by the fact that different 
bones throughout the skeleton require a specific strain magnitude to maintain bone mass. 
Consequently, different bones respond differently to increases or decreases in loading, 
depending on the sensitivity of the mechanostat. Osteocytes, i.e., cells embedded in the bone 
matrix, are believed to be the major bone cells involved in sensing and transduction of 
mechanical loads (Pivonka et al., 2018). 
 
In an article published by Herrmann et al. (2015), high levels of physical activity have been 
found to optimise skeletal development early in life, thus preventing age-related bone loss and 
osteoporotic fractures. These authors concluded that muscle strength and muscle mass play an 
important role in bone development during growth after school-based interventions an 
osteogenic effect of weight bearing exercise such as jumping, or ballgames has been observed. 
Herrmann et al. (2015) stated that the effect of high-impact physical activity has been largely 











2.7.8 Bone remodeling  
 
Bone quality is an amalgamation of all the factors that, in addition to bone mass, determine 
how well the skeleton can resist fracture, including micro-architecture accumulated 
microscopic damage, the quality of collagen, the degree of mineralisation, and the rate of bone 
turnover. According to Dempster (2011), bone remodeling, specifically the balance between 
the formation of new bone and bone resorption (breakdown of bone), is the biological process 
that maintains a healthy skeleton and mediates changes in the factors that influence bone 
strength. Remodeling does not change the shape of bone, but is vital for bone health, as it 
repairs skeletal damage that can result from repeated stresses by mending small damaged areas 
(Dempster 2011). Remodeling also serves to renew the cellular elements of bone, in particular, 
the osteocytes, which are derived from osteoblasts. Osteocytes play a key role in bone health 
by regulating the remodeling process, among many other functions. Dempster (2011) also 
stated that in addition, remodeling prevents the accumulation of too much old bone, which can 
lose its resilience and become brittle.  
 
Zheng et al. (2016) explain that bone remodeling involves coordinated actions of osteoclasts 
(cells that break down bone) to remove bone matrix through resorption of old bone, followed 
by osteoblasts (cells that form bone) creating new bone through the secretion and 
mineralisation of new bone matrix.  Both processes are important for the maintenance of bone 
volume and structure. 
 
When the balance between the formation of new bone and bone resorption is impaired and 
there is greater bone breakdown than replacement, bone loss occurs. Therefore, disease 
processes and pharmacologic agents that impact bone remodeling will ultimately influence 
bone’s resistance to fracture (Dempster, 2011).  
 




Imbalances of remodeling can result in gross perturbations in skeletal structure and function, 
and potentially to morbidity and shortening of lifespan.  Most adult skeletal diseases are due to 
excess osteoclastic activity, leading to an imbalance in bone remodeling which favors 
resorption. Such diseases would include osteoporosis, periodontal disease, rheumatoid arthritis, 
multiple myeloma and metastatic cancers (Boyle et al., 2003).  
 
2.7.9 Bone geometry 
 
The shape of bone could influence its propensity to fracture.  Research has identified hip axis 
length as a characteristic of femur shape that could influence fracture risk. According to Aloia 
(2008), shorter hip axis length protects against osteoporotic fractures. 
 
According to Knapen et al. (2007) Dual-Energy X-ray Absorptiometry-Bone Mineral Density 
(DXA-BMD) is still the method of choice used in the clinical evaluation of hip fracture risk; 
however, it has been stipulated that its uncritical use may lead to size-related artefacts in the 
estimation of bone strength and the identification of fracture risk.  Therefore, the ultimate 
concern in studying bone status is bone strength.  Holding other variables constant, strength 
will increase both as bone mass increases and as bone size increases.  When estimating bone 
strength, two strategies that also compensate for bone dimensions have been proposed.  First, 
it is encouraged that densitometric comparisons between groups are based on BMC rather than 
DXA-BMD. Second, bone dimensions are used as independent determinants for bone strength. 
Important geometric parameters are the hip axis length (HAL) and the femoral neck width 
(FNW).  Patients with a low DXA-BMD, or who have experienced a hip fracture, had an 
increased FNW, suggesting an attempt to compensate for the increased fracture risk at this 
critical site.  On the other hand, it seems obvious that at comparable DXA-BMD, a larger FNW 
will positively contribute to bone strength. In this way it is understandable that an increase in 
BMC may contribute to bone strength, although it should be kept in mind that it is not the mass 
per se, but the distribution of mass that is crucial for bone strength (Knapen et al., 2007). 




2.8 Diagnosis of osteoporosis 
 
Under the auspices of the World Health Organization (WHO, 1994), a panel of experts has 
met periodically.  They first convened as a group of experts in 1994 to assess fracture risk 
and its application to screening for postmenopausal osteoporosis.  The scientific group 
defined osteoporosis based on BMD (WHO, 1994). 
 
According to the WHO’s diagnostic classification (1994), osteoporosis is defined by BMD 
at the hip or lumbar spine that is less than or equal to 2.5 SD below the mean BMD (T-score 
≤-2.5) of a young-adult reference population.  The National Osteoporosis Foundation of 
South Afrika (NOFSA, 2010) recommend that the T-score should be used when diagnosing 
postmenopausal women, and that the Z-score should be used in premenopausal women 
(Hough et al., 2010).  Z-score is the number of SD above or below the expected BMD for the 
patient's age and sex. A Z-score of –2.0 or lower is defined as either “low BMD for 
chronological age” or “below the expected range for age,” and those above –2.0 are “within 
the expected range for age” (Qaseem et al., 2017). 
 
Osteoporosis is regarded as a risk factor for fracture just as hypertension is for stroke. The 
risk of fractures is highest in those with the lowest BMD; however, most fractures occur in 
patients with low bone mass rather than those classified as having osteoporosis, because of 
the large number of individuals suffering from low BMD (Siris et al., 2014). 
 
As BMD has a Gaussian distribution, it is difficult to define a cutoff for osteoporosis diagnosis 
(T-score <-2.5). However, the majority of individuals who have low-trauma fractures do not 
have osteoporosis with DXA (i.e., T-score <-2.5), and some of them have no decreased BMD 
at all. Some medical conditions (spondyloarthropathies, chronic kidney disease and mineral 
bone disorder, diabetes, obesity) or drugs (glucocorticoids, aromatase inhibitors) are more 
prone to cause fractures with subnormal BMD. In the situation of fragility fractures with 




subnormal or normal BMD, clinicians face a difficulty, as almost all the pharmacologic 
treatments have proved their efficacy in patients with low BMD and in patients with a previous 
fragility fracture (especially vertebra or hip).  It is recommended to treat patients with a major 
fragility fracture even if areal BMD T- score is above -2.5 (Lespessailles et al., 2017). 
 
Osteopenia is defined as a bone density between 1.0 and 2.5 SD below the mean for young 
adult women.  The T-score is defined as the number of SD the patient’s BMD is above or below 
the sex-matched mean reference value of young adults. The T-score thus provides a comparison 
of the patient’s BMD to the mean PBM.  The Z-score is defined as the number of SD the 
patient’s BMD is above or below the sex-matched mean reference value for individuals of the 
same gender and age.  The Z-score, therefore, enables a comparison of the patient’s BMD to 
individuals of the same age (Syed & Khan, 2002). 
 
Eriksson et al. (2018) studied a group of 45 obese, non-diabetic, antipsychotic-treated patients.  
The mean age of the patients was 35.8 years.  With one exception, all sex and age-adjusted 
BMD Z-score measurements were within the normal range.  They noted that the presence of 
marked obesity might partly explain their findings. 
 
A cross-sectional study that consisted of 5 892 consecutive non-institutionalised men and 
women who were referred to the Isfahan Osteoporosis Diagnosis and Body Composition 
Center was done by Salamat et al. (2016).  Compared with men ≥50 years, and postmenopausal 
women with BMI <25 kg/m2, the age-adjusted risk of femoral neck osteoporosis was more than 
four-fold lower in those with a BMI ≥30.  They found that the association between BMI and 
osteopenia was similar. When a Z-score ≤–2.0 was used as alternative analysis to diagnose low 
bone mass in premenopausal women and men <50 years, the results were very similar to results 
of T-score ≤–2.5 comparisons.  In men, premenopausal women, and postmenopausal women, 
there was a negative correlation between age and BMD indicators, and a positive correlation 
between BMI and BMD indicators; the strongest correlation coefficients were between age and 
BMD in the femoral neck, and the weakest correlations were between age and L1 to L4 BMD. 
Their study showed that the association between age and BMD was stronger in postmenopausal 




women. In conclusion, in men, premenopausal women, and postmenopausal women, the 
correlation between BMI and BMD indicators remained after age-adjustment. In their study, 
obesity significantly decreased the risk for osteoporosis, osteopenia, and low bone mass in all 
participants. They did not identify any influence of gender and menopause on the obesity 
paradox in osteoporosis, despite significant differences in characteristics between both genders 
and menopause status. 
 
Alarkawi et al. (2015) indicate that the femoral neck region is widely regarded as the optimum 
site for osteoporosis diagnosis and fracture risk assessment, because it has good predictive 
value for all major osteoporotic fractures, and because lumbar spine bone density is often 
spuriously elevated by degenerative changes.  The diagnosis of osteoporosis based on a  
T-score of ≤ -2.5 should remain an important way to identify an individual with increased 
risk for fracture development. Bone density testing is recommended based on age and risk 
factor status in both men and women.  According to Siris et al. (2014), only a small proportion 
of older men and women have a BMD test. Many who do receive the test may still not  be 
recognised as having an elevated fracture risk, because their scores reflect “osteopenia,” 
which in some instances does indicate a high risk based on elevated age or prior fracture 
history or other validated risk factors. Prior fracture affords the highest risk for future 
fracture, yet an older patient with a hip fracture may not be diagnosed as having osteoporosis, 
unless the patient has a BMD test with a T-score of ≤ -2.5, and the majority of hip fracture 
patients have T-scores that are better than −2.5.  An incident vertebral fracture strongly 
predicts an increased risk of another vertebral fracture as soon as within the next year.  Most 
fractures occur in people with low bone mass, not T-score osteoporosis, because a greater 
number of people have osteopenia than osteoporosis as defined by BMD.  The failure to 
detect clinical osteoporosis when it is present likely contributes to the current lack of 








2.9 Complications associated with osteoporosis  
 
Osteoporosis is associated with an increased risk of fracture development.  Vertebral fractures 
result in the development of dorsal kyphosis and height loss and can also result in chronic back 
pain (Syed & Khan, 2002).  A significant proportion of vertebral fractures are not identified, 
and only one-third of vertebral fractures receive medical attention.  Hip fractures are associated 
with a significant increase in morbidity, and approximately a 20% mortality rate within the first 
year following a hip fracture. Clinically, the diagnosis of osteoporosis is made in its advanced 
stages and usually following a bone fracture. As the presenting fracture is associated with an 
increased risk of subsequent fractures, it is important to diagnose and treat osteoporosis prior 
to the development of the first fracture (Syed & Khan, 2002).  
 
Paolucci et al. (2016) stated that osteoporosis and sarcopenia are often associated in the elderly.  
The number and size of muscle fibers are reduced, and there is a preferential loss of type II 
fibers.  They stated that age-related immobilisation also increases the risk of muscle atrophy 
and bone loss, boosting the risk of fractures. The elderly is at greater risk of debilitating postural 
changes due to several factors, particularly the involutional loss of functional muscle motor 
units and the higher prevalence of osteoporosis in these subjects. This muscle loss can 
contribute to osteoporosis-related skeletal changes.  Muscle weakness has been suggested to 
be related to a progressive decline in bone mass, with consequent axial kyphosis, even in the 
absence of vertebral fractures.   
 
Bone has trabecular and cortical components. Trabecular bone predominates in vertebrae and 
the proximal femur, whereas cortical bone is prominent in the long bone shafts.  Trabecular 
remodeling occurs at a rate of approximately 25% per year, while the cortical rate is 
approximately 3% per year. Thus, changes in BMD occur more quickly and have greater 
clinical implications in trabecular bone, which is consistent with the prevalence of vertebral 
and femoral fractures in patients with osteoporosis (Lash et al., 2009). 




In a study done by Petit et al. (2010) they suggested that in patients with T2DM, trabecular 
bone mass and structure are intact and perhaps even enhanced, whereas the cortical 
compartment is preferentially compromised.  This is noteworthy because: (a) the cortex makes 
up 80% of the skeleton, (b) cortical bone is present primarily at non-vertebral sites, and (c) in 
T2DM, most of the fractures occur at sites that are rich in cortical bone.  Increased cortical 
porosity has been reported at the radius in female diabetics who have fractured, as measured 
by intracortical pore volume fraction via high-resolution peripheral quantitative computed 
tomography. Although endosteal cortical remnants can be mistakenly interpreted as 
trabeculae, true increases in cortical porosity could be an important cause of increased fracture 
risk in T2DM patients because it reduces bone strength, yet is undetectable by DXA (Leslie et 
al., 2012). 
 
In an observational study done by Paruk et al. (2017) the incidence rates and relative risk ratios 
of osteoporotic hip fractures were calculated in the black population, aged 60 years and older, 
residing in the eThekwini region of South Africa. All subjects presenting with a minimal 
trauma hip fracture. Paruk’s study represent the largest number of hip fractures recorded in 
black Africans. Although the incidence rate was approximately tenfold higher than previously 
recorded, it remains amongst the lowest globally.  
  
2.10 Bone densitometry 
 
Today, DXA is still considered the golden standard for the measurement of BMD because of 
its reproducibility, large normative data, non-invasive nature, short analysis time, and minimal 
radiation exposure (Garg & Kharb, 2013). In clinical practice, treatment decisions are based on 
BMD measurements obtained from DXA and the WHO classification for the diagnosis of 
osteoporosis (WHO, 1994). The WHO criterion applies to BMD of three skeletal sites, the hip, 




lumbar spine or forearm. The hip and spine are the two most commonly used skeletal sites 
(Arabi et al., 2007).  
 
2.10.1  What is DXA scanning? 
 
Non-invasive bone densitometry utilizing X-ray absorptiometry enables accurate evaluation 
of bone mass and the diagnosis of osteoporosis in asymptomatic individuals prior to fracture.  
DXA can evaluate bone quality through indirect analysis of micro- and macro-architecture of 
the bone, which can improve the prediction of fracture risk (Choi, 2016).  BMD testing is a 
vital component in the diagnosis and management of osteoporosis regarding bone strength.  
Instead of a specific threshold, fracture risk increases exponentially as BMD decreases.  
 
2.10.2 Technical advantages 
 
DXA is a quick method that is accurate (exact measurement of BMD), precise (reproducible), 
and flexible (different regions can be scanned), and is performed with a low radiation dose 
(Lorente-Ramos et al., 2011). These authors explained that a DXA scanner consists of a  
low-dose x-ray tube with two energies for separating mineral and soft-tissue components, 
and a high-resolution multi-detector array. The devices have one of two different systems: a 
fan-beam device that emits alternating high (140 kVp) and low (70–100 kVp) x-rays and 
sweeps across a scan area, or a constant x-ray beam with a rare-earth filter and  
energy-specific absorption, which separates photons of higher (70 keV) and lower (40 keV) 
energy (Lorente-Ramos et al., 2011).  
 




Although different types of DXA systems are available, all of them operate on similar 
principles.  A radiation source is aimed at a radiation detector placed directly opposite to the 
site to be measured.  Early DXA systems used pencil beam geometry and a single detector, 
which was scanned across the measurement region. Modern full-table DXA scanners use a  
fan-beam source and multiple detectors, which are swept across the measurement region.  DXA 
technology can measure virtually any skeletal site, but clinical use has been concentrated on 
the lumbar spine, proximal femur, forearm and total body. The patient is placed on a table in 
the path of the radiation beam. The source/detector assembly is then scanned across the 
measurement region. The attenuation of the radiation beam is determined and is related to the 
BMD.  Because DXA scanners use two X-ray energies in the presence of three types of tissue 
(bone mineral, lean tissue and adipose tissue), there are considerable errors arising from the 
inhomogeneous distribution of adipose tissue in the human body (El Maghraoui & Roux, 
2008).  Syed and Khan (2002) stated that by using the dual energy beams, corrections for soft 
tissue are made, enabling the assessment of BMD.  
 
2.10.3   Possible artefacts 
 
Images should be assessed for artefacts, which should be excluded from the region of interest 
(ROI). Artefacts include dense objects such as piercings, catheters, surgical material, and 
contrast medium, such as barium and myelographic agents. Calcifications superimposed on the 
ROI should be noted as causes of increased BMD (Lorente-Ramos et al., 2011). 
 
DXA measurement at the hip is the best predictor of future hip fracture risk. In 
postmenopausal women and men age 50 and older, the WHO (1994) diagnostic T-score 
criteria (normal, low bone mass, and osteoporosis) are applied to BMD measurement by 
central DXA at the lumbar spine and femoral neck (Cosman et al., 2014). 
 




As with many other diagnostic examinations, DXA scans should be critically assessed by the 
interpreting physician and densitometrist for abnormalities that may affect BMD 
measurements. In clinical practice, recognition of diverse artefacts and disease processes that 
may influence BMD results can be of major importance in the optimal interpretation of DXA 
scans.  Physicians not directly involved in the performance and interpretation of DXA should 
familiarise themselves with the procedure to be able to detect common positioning and 
scanning problems, to know what should appear on a report, what questions to ask if the 
necessary information is not on the report, how to apply the results in patient management, and 
when to do and how to interpret a second measurement to monitor treatment.   
 
2.10.4 Indications and contraindications 
 
The decision to perform bone density assessment should be based on an individual’s fracture 
risk profile and skeletal health assessment. BMD is not recommended in children or 
adolescents and is not routinely indicated in healthy young men or premenopausal women 
unless there is a significant fracture history or there are specific risk factors for bone loss 
(Cosman et al., 2014). According to Cosman et al. (2014), BMD testing is important in the 
following individuals: 
 
• Women aged 65 and older and men aged 70 and older, regardless of clinical risk 
factors. 
• Younger postmenopausal women, women in the menopausal transition, and men age 
50 to 69 with clinical risk factors for fracture. 
• Adults who have a fracture at or after age 50. 
• Adults with a condition (e.g., rheumatoid arthritis) or taking medication (e.g., 
glucocorticoids in a daily dose > 5 mg prednisone or equivalent for > 3 months) 
associated with low bone mass or bone loss. 




The International Society for Bone Densitometry (ISCD) guidelines recognise the need to 
identify individuals at risk for osteoporosis (ISCD, 2002).  The United States Preventive 
Services Task Force (USPSTF) released guidelines for osteoporosis screening on 16 September 
2002. The USPSTF is an independent panel of experts in primary care and prevention. This 
panel systematically reviews the evidence of effectiveness and develops recommendations for 
clinical preventive services.   
 
Contraindications for bone densitometry include pregnancy, although radiation exposure with 
central DXA assessments is minimal (1–5 microsieverts per scan).  In individuals who have 
recently had gastrointestinal contrast or a nuclear medicine test, BMD should be delayed by at 
least 72 hours, as these tests can affect the results of the scan (Syed & Khan, 2002).  
 
2.10.5 Measured DXA sites 
 
DXA calculates BMD (grams per square centimeter) as BMC (in grams) divided by the 
projected bone area (square centimeters). As a two-dimensional projectional (areal) technique, 
DXA does not fully account for skeletal size, as it cannot compensate for differences in the 
unmeasured third dimension (depth). Thus, a larger bone will tend to have higher BMD than a 
smaller bone, and comparison of BMD between individuals with different bone sizes can be 
misleading (Leslie et al., 2012). 
 
BMD assessments should include DXA evaluation of the hip and spine. Both sites are of value 
in global fracture prediction (Alarkawi et al., 2015).  Spine scans are of benefit in the younger 
postmenopausal female, as the spine is a site rich in cancellous bone and is often the first site 
to reflect early postmenopausal bone loss.  In the elderly population, as the spine assessments 
are more likely to be falsely elevated, it is particularly important to review the hip scan and 
consider intervention based on the bone density at the hip site. The spine assessment may be 




falsely elevated in the presence of extensive degenerative change, aortic calcification, or 




Figure 2.6:   Anteroposterior (AP) spine scan that illustrates abnormality at L2 with 
sclerosis, resulting in a falsely elevated lumbar spine bone density.  Sclerosis 
or other obvious skeletal abnormalities on the spine scan should be further 
evaluated with spinal X-rays. This patient had radiographic confirmation of 
Paget's disease at L2 (adapted from Syed & Khan, 2002). 
 
In the spine, absent bone (laminectomy or spina bifida) or vertebral rotation (idiopathic 
scoliosis) will spuriously lower BMD. All evaluable vertebrae should be used, but vertebrae 
that are affected by local structural change should be deleted from the analysis. Most agree that 
decisions can be based on two vertebrae; the use of a single vertebra is not recommended. If 
all vertebrae are affected, the spine should be reported as ‘invalid,’ with no BMD or T-score 
results given. Figure 2.7 illustrates examples from the common spine, and Figure 2.8 illustrates 
hip scanning problems (El Maghraoui & Roux, 2008). 
 
Figure 2.7 illustrates some pitfalls when scanning the lumbar spine. 
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                                               D                                                          E 
Figure 2.7:  Examples of some common spine scanning problems:  A) The spine is too close   
                    to the right side of the image B) Vertebral levels are misidentified C) Metal button   
                    over L4 D) Scoliosis and osteophytes at L3-L4 E) Laminectomy (adapted from El   
                    Maghraoui & Roux, 2008). 
 
It is recommended that bone density at the lumbar spine be evaluated from the first to the fourth 
lumbar vertebrae. At the hip, the diagnosis of osteoporosis can be based on the T-score obtained 
at the femoral neck, total hip, or trochanteric regions. It is not recommended to base the 
diagnosis solely on Ward’s region, as this area is too small to be adequately accurate or precise. 
The total hip bone density provides greater precision than the femoral neck, as a larger area of 
the skeleton is evaluated. The use of additional peripheral sites is of value in conditions such 
as primary hyperparathyroidism, in which preferential bone loss occurs at sites rich in cortical 
bone.  The one-third radial site reflects the effect of primary hyperparathyroidism to a greater 
degree than BMD measurement at the lumbar spine or the total hip, as this site is essentially 
purely cortical bone (Syed & Khan, 2002).  




One important way to describe bone quality is to assess its micro-architecture. Bone  
micro-architecture contributes to the mechanical strength of bone and, thus, to its ability to 
withstand fractures. Bone loss is often accompanied by deterioration in bone architecture, 
resulting from a decrease in the number of trabeculae or cancellous bone, increased 
intertrabecular distances, and a loss of trabecular connectivity. In addition, a reduction in the 
thickness of cortical bone and an increase in the porosity of trabecular bone can result in 
fragility of the femoral neck. Osteoporotic bone is, hence, called “porous” (Jackuliak & Payer, 
2014). 
 
The hip bone density can be falsely elevated in the presence of osteoarthritis due to the presence 
of increased bone mineral deposition along the medial aspect of the femoral neck. The presence 
of hardware such as Harrington spinal rods or hip replacements precludes a useful BMD 
assessment at the affected site. In situations where differing T-scores are obtained at the two 
skeletal sites, the diagnosis of osteoporosis is based on the lower T-score (Syed & Khan, 2002).  
 
In hip scanning, it is important to avoid undesired bone. The anatomic landmark selected for 
femoral neck ROI placement is the greater trochanteric notch (Lorente-Ramos et al., 2011). 
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Figure 2.8:  Examples among some common hip scanning problems:  A) The scan did not   
                    go far enough laterally, and part of the femoral head is missing. B) The femur is   
                    adducted. C) The femur is abducted.  D)  Suboptimal internal rotation (too much  
                    of the lesser trochanter is showing).  E)  Abnormal bone (history of hip fracture   
                    and osteosynthesis). (Adapted from El Maghraoui & Roux, 2008). 
 
The rate of bone loss differs according to the age of the patient and the skeletal site. In the  
peri-menopausal period and in the early post-menopausal period, bone loss occurs mainly at 
the spine reflecting the effect of estrogen deficiency on trabecular bone, thus by measuring the 
hip only, the diagnosis of osteoporosis may be missed in this group of patients (Arabi et al., 
2007).  
 
The ISCD recommends obtaining BMD measurements of the AP spine and hip.  The lateral 
spine and Ward’s triangle region of the hip should not be used for diagnosis, as these sites 




overestimate osteoporosis, and results can therefore be falsely positive.  Evidence suggests that 
the femur (neck or total hip) is the optimum site for predicting the risk of hip fracture, and the 
spine is the optimum site for monitoring response to treatment. Thus, many authors recommend 
hip measure alone for the fracture risk assessment.  In very obese patients, those with primary 
hyperparathyroidism, or those in whom the hip or the spine, or both, cannot be measured or 
interpreted, BMD may be measured in the forearm, using a 33% radius on the no dominant 
forearm (El Maghraoui & Roux, 2008).  
 
2.10.6 Patient positioning during BMD analysis 
 
An important component of DXA interpretation involves scrutinising the skeletal images to 
assess patient positioning, correctness of edge detection, potentially confounding artefacts, and 
placement of margins to delineate ROIs (Lewiecki et al., 2016).  
 
Tuna et al. (2017) state that, when there is inaccuracy in the labeling of vertebral bodies, bone 
edges, and ROI, these errors are defined as analysis errors.  A non-optimal process may lead to 
over diagnosis or under diagnosis (Tuna et al., 2017). 
 
Appropriate patient positioning is essential for optimising BMD measurement. The patients are 
placed in the supine position for AP imaging of the lumbar spine and proximal femur (Lorente-
Ramos et al., 2011).  
 
A scan with the correct positioning of the spine is illustrated in Figure 2.9.  The patient lies 
straight on the table (spine is straight on the image), not rotated (spinous processes are 
centered), and centered in the ROI (roughly equal soft tissue fields on either side of the spine). 
The scan should include part of the lowest vertebra with ribs (which is usually T12) and low 
enough to show the pelvic brim (which is usually the level of the L4–L5 interspace). Most 




testing centers will elevate the patient’s knees with a foam block (hip at a 90º angle to the spine) 




Figure 2.9:  A scan with correct positioning of the spine (adapted from El Maghraoui 
                    & Roux, 2008) 
 
For proper positioning of the hip (Figure 2.10), the patient should have the femur straight on 
the table (shaft parallel to the edge of the picture), with 15–25º of internal rotation, which can 
be achieved using positioning devices (Baniak et al.,2014). Internal rotation may be improved 
by having the patient flex the foot before doing the internal rotation, and then relaxing the foot 
after the strap is in place. This amount of internal rotation presents the long axis of the femoral 
neck perpendicular to the X-ray beam, providing the greatest area and the lowest BMC (and 
the lowest BMD), and is confirmed on the scan by seeing little or none of the lesser trochanter 
























    
   
 
Figure 2.10:  Proper positioning of the hip (adapted from El Maghraoui & Roux, 2008) 
 
2.10.7 Scan analysis 
 
The software marks regions of interest in the spine and hip, but the technologist can and should 
adjust if needed. The spine region of interest consists of the L1 through L4 vertebrae.  Correct 
placement of the top and bottom of the spine ‘box’ is critical. The intervertebral lines can be 
moved or angled, if necessary. There must be sufficient soft tissue on both sides of the spine; 
otherwise BMD will be underestimated. The hip regions of interest include the femoral neck, 
trochanter and total hip (Figure 2.11) (Baniak et al., 2014). The default hip analysis includes a 
midline that must be placed correctly for the other sites to be identified correctly. The preferred 
position for the rectangular femoral neck box differs for different manufacturers. For Discovery 
QDR series (HOLOGIC, USA) the box is on the distal part of the femoral neck (El Maghraoui 
& Roux, 2008). 
 
The correct numbering of the vertebral bodies is the main goal in DXA of the lumbar spine. 
The indicators of correct positioning are as follows: the ribs appear at T12, the largest 




transverse processes are L3, the vertebral area values increase from L1 to L4, BMD increases 
from L1 to L3, and the BMD of L4 is similar to or slightly less than that of L3. Sometimes 
radiographs are necessary for correlation. Altered vertebrae (deformed or with lesions or 
artefacts in them) should be excluded from the analysis. If only one vertebral body is left, the 
region is not useful for diagnosis (Lorente-Ramos et al., 2011).  
 
The left proximal femur shows four ROIs and include the femoral neck, trochanter, 
intertrochanteric region, and Ward's triangle.  The total hip comprises four RIOs.  The image 
includes the entire femoral head and at least 1 cm under the region of the lesser trochanter, 
which should not be seen owing to rotation.  As seen in Figure 2.11, the femoral axis is straight. 
Figure 2.12 indicates the wrong positioning of the patient showing the lesser trochanter 
(Lorente-Ramos et al., 2011). 
 
             
 
Figure 2.11:  ROI of the proximal femur      Figure 2.12:  ROI of the proximal femur  
(adapted from Lorente-Ramos, 2011)            showing the lesser trochanter (adapted 








2.10.8 Interpretation of results and classification  
 
DXA measurement of the hip and spine is the technology used to establish or confirm a 
diagnosis of osteoporosis, predict future fracture risk, and monitor patients. Areal BMD is 
expressed in absolute terms of grams of mineral per square centimeter scanned (g/cm2), and as 
a relationship to two norms:  compared to the BMD of an age-, sex-, and ethnicity-matched 
reference population (Z-score) or compared to a young-adult reference population of the same 
sex (T-score).  The difference between the patient's BMD and the mean BMD of the reference 
population, divided by the SD of the reference population, is used to calculate T-scores and  
Z-scores (Baniak et al., 2014).  PBM is achieved in early adulthood, followed by a decline in 
BMD.  The rate of bone loss accelerates in women at menopause and continuous to progress 
at a slower pace in older postmenopausal women and in older men.  An individual's BMD is 
presented as the SD above or below the mean BMD of the reference population. The BMD 
diagnosis of normal, low bone mass (osteopenia), osteoporosis, and severe or established 
osteoporosis is based on the WHO diagnostic classification (1994), as seen in Table 2.2 
(Cosman et al., 2014). 
 

















Table 2.2:  Defining osteoporosis by BMD T-score (adapted from Cosman et al., 2014).  
 
WHO definition of osteoporosis based on T-score 
Classification BMD T-score 
Normal 
Within 2 SD of the mean level for a young adult 
reference population 
T-score at -1.0 and 
above  
Low bone mass 
(osteopenia) 
Between 1.0 and 2.5 SD below that of the mean 
level for a young-adult reference population 
T-score between -
1.0 and -2.5 
Osteoporosis 2.5 SD or more below that of the mean level for a 
young-adult reference population 





2.5 SD or more below that of the mean level for a 
young-adult reference population with fractures 
T-score at or below 






















Table 2.3:  Defining osteoporosis by BMD Z-score (adapted from Qaseem et al., 2017) 
 
NOFSA definition of expected range for age based to Z-score 
Classification BMD Z-score 
 
Within the expected 
range for age 
 
 
The number of SD above the expected BMD for the 
patient's age and sex 
 
Z-score above -2.0 
 
Below the expected 
range for age 
 
 
The number of SD below the expected BMD for the 
patient's age and sex 
 
Z-score below -2.0 
 
 
The most important information to check is the correct identification of the patient, his date of 
birth and the sex and ethnicity which are mandatory to calculate T-scores. Sex is used by all 
manufacturers to calculate T-scores (i.e. T-scores for women are calculated using a female 
normative database, while T-scores for men are calculated using a male normative database). 
Although all manufacturers use race in calculating Z-scores, there is inconsistency in the way 
race is handled when calculating T-scores. Hologic is using race in calculating T-scores (i.e. 
T-scores for Caucasians are calculated using a Caucasian normative database, T-scores for 
Blacks are calculated using a normative database for Blacks); however, GE Lunar (GE Health 
care, USA) and recent Hologic machines use the database for young normal Caucasians to 
calculate T-scores, regardless of the race of the subject (Lo et al., 2016). The ISCD 
recommends the latter approach for use in North America, since using race-adjusted T-scores 
results in a similar prevalence of ‘osteoporosis’ in every racial group, even though age-specific 
fracture rates can be very different (El Maghraoui & Roux, 2008). 
  




Proper positioning of the hip is necessary for appropriate interpretation of the scan. The hip 
should be positioned such that the femoral shaft is straight, and the lesser trochanter is barely 
visible. The femoral neck region of interest box should not overlap portions of the ischium or 
the greater trochanter, as this can result in a falsely elevated assessment of BMD.  As illustrated 
in Figure 2.13, the hip has not been adequately internally rotated, and the lesser trochanter is 
visible. Inadequate internal rotation results in a higher bone density than achieved with proper 
positioning of the hip. In this scan, the femoral neck region of interest box has also been 




Figure 2.13:  Poor positioning of a hip scan (adapted from Syed & Khan, 2002)                 
                        
 
2.10.9 T-score and Z-score 
 
The scanner calculates BMD in g/cm2. A reference database is consulted, and values and curves 
are obtained.  The main parameters are T-scores, which represents the SD by which the BMD 
differs from the mean BMD of a young adult reference population of the same ethnicity and 




sex, and Z-score, which is the SD by which the BMD differs from the mean BMD of a healthy 
population of the same ethnicity, sex and age as the person undergoing DXA (Lorente-Ramos 
et al., 2011). 
 
The T-score is defined as the number of SD the patient’s BMD is above or below the  
sex-matched mean reference value of young adults. The T-score thus provides a comparison of 
the patient’s BMD to the mean PBM (Baniak et al., 2014).  The Z-score is defined as the 
number of SDs the patient’s BMD is above or below the sex-matched mean reference value for 
individuals of the same gender and age.  The Z-score, therefore, enables a comparison of the 
patient’s BMD to individuals of the same age (Carey & Delaney, 2010).  
 
2.10.10 Risk factors influencing DXA results 
 
Low BMD has been recognised as a good predictor of osteoporotic fracture risk. Nevertheless, 
although widely used, a major limitation of BMD measurement is that a substantial degree of 
BMD overlap exists between subjects with and without subsequent fractures. An additional 
explanation for this is that BMD does not capture all the factors that contribute to bone strength. 
Among these factors is trabecular bone micro-architecture, which also appears to be a 
significant determinant of bone strength and is complementary to bone density. Another 
limitation of BMD measurement is that they disproportionately evaluate cortical bone 
depending on the skeletal site measured, which has a relatively slow rate of turnover (Jackuliak 
& Payer, 2014). 
 
Failure to follow standard procedures may result in invalid data, which can be misleading and 
potentially harmful for patient care.  Examples of DXA errors abound. These include incorrect 
patient positioning and/or analysis, failure to consider confounding artefacts that affect BMD 
values, and inappropriate reference database use for T-score derivation. Additional errors 




include failure to recognise densitometer drift or shift that could lead to reporting an 
inappropriate BMD change, thus leading to alteration of therapy, failure to change therapy, 
and/or unnecessary diagnostic studies. Another common error is failure to perform precision 
assessment, resulting in inability to distinguish between an apparent BMD difference that is 
simply within the range of error of the test versus one that is statistically significant (Lewiecki 
et al., 2016).  
 
Physiologic discordance is related to the skeleton’s natural adaptive reaction to normal external 
and internal factors and forces. Mechanical strain especially related to weight bearing plays a 
key role in this kind of discordance. An example of this type of discordance is the difference 
observed between the dominant and non-dominant total hip.  The explanation is that weight 
bearing can cause rise in bone density, especially in the hip and femur regions.  Moreover, the 
spine and hips usually start out with different T-scores (the spine is said to reach peak at least 
5 years before the hip).  Finally, another observation is that bone loss observed with age in an 
individual may be more rapid and important in trabecular than cortical bone. Trabecular bones 
(typical of lumbar area) are known to have a more rapid rate of deprivation in early 
postmenopausal state in comparison with cortical bone (typical of proximal femur) 
(Milovanovic et al., 2017). 
 
Another type of discordance is described as pathophysiologic discordance.  Common examples 
observed in the elderly include vertebral osteophytosis, vertebral end plate and facet sclerosis, 
osteochondrosis, and aortic calcification (Lu et al., 2016). Another important cause in younger 
patients is ankylosing spondylitis syndesmophytes.  The abnormal calcium deposition within 
the field of the DXA ROI leads to the falsely elevated spine T-score.  A second subtype is a 
true discordance resulting from a more decreased BMD in the lumbar spine than the hips.  
Indeed, most of the aetiologies of secondary osteoporosis (such as glucocorticoid excess, 
hyperthyroidism, malabsorption, liver disease and rheumatoid arthritis) affect the spinal 
column first.  This will lead to higher prevalence of lumbar osteoporosis (Sheu & Diamond, 
2016). 
 




Anatomic discordance is the result of differences in the composition of bone envelopes tested.  
An example is the difference in T-scores found for the AP lumbar spine and the supine lateral 
lumbar spine in the same patient (Lee et al., 2017). 
 
The premenopausal period is important for bone health and prevention of future fractures but 
measuring BMD at only one site may not be sufficient to determine therapeutic strategies for 
low BMD in premenopausal women due to the presence of Z-score discordance (Park et al., 
2016).  They investigated Z-score discordance in addition to contributing factors of idiopathic 
low BMD in healthy premenopausal Korean women aged 18-50 years.  Low BMI, low vitamin 
D level, and low body muscle mass were associated with low BMD even in these women.  They 
found that low BMI and a low vitamin D level were risk factors for low femoral neck BMD, 
but not for low lumbar spine BMD, and suggested that BMD discordance in premenopausal 
women should be considered to provide information on correctable factors affecting low BMD 
in younger populations.  
 
Artefactual discordance occurs when dense synthetic man-made substances are within the field 
of ROI of the test: e.g. barium sulphate, metal from zipper, coin, clip, or other metallic objects 
(Doroudinia & Colletti, 2015). 
 
Errors in patient positioning, skeletal site, artefacts removal, and demographic data are 
considered improper acquisition.  According to Tuna et al. (2017) when there is inaccuracy in 
the labeling of vertebral bodies, bone edges, and ROI, these errors are defined as analysis 
errors. 
 
Alavizadeh et al. (2014) stated that the bone loss after spinal cord injury is different from what 
happens during a normal aging process, and that it is mainly because of particular mechanical, 
neurovascular and hormonal changes that occur in these patients.  According to them, bone 
loss happens at a greater pace in trabecular bones, resulting in T-score discordance.  T-score 
discordance might be troublesome for the physicians, and may result in negative outcomes in 




the patients, as a true osteoporotic patient must not go undiagnosed, and a healthy patient must 
not be falsely diagnosed as osteoporotic.  
 
2.10.11 Ethnic differences in bone density also increase risk of fracture rate 
 
A study done by Leslie et al. (2012) found that the available data highlighted the complex 
ethnic variations in BMD, which only partially accounted for observed variations in fracture 
rates. Factors contributing to ethnic differences include genetics, skeletal size, body size and 
composition, lifestyle, and social determinants. Despite BMD differences, the gradient of risk 
for fracture from BMD and other clinical risk factors appears to be similar across ethnic groups. 
Furthermore, BMD variation is greater within an ethnic population than between ethnic 
populations. New imaging technologies have identified ethnic differences in bone geometry, 
volumetric density, micro-architecture, and estimated bone strength that may contribute to a 
better understanding of ethnic differences in fracture risk.  The conclusion was that factors 
associated with ethnicity affect BMD and fracture risk through direct and indirect mechanisms 
(Leslie et al., 2012). 
 
Racial differences in BMD values have been well recognised. African-Americans have a higher 
bone density than Caucasians.  It is thus important to compare women to the appropriate ethnic 
normative reference data. The relationship between BMD and fracture risk is not well defined 
in the non-Caucasian population. Although Asians have a lower bone density than Caucasians, 
data from the National Health and Nutrition Examination Survey (NHANES) study in fact have 
demonstrated that Asian women have a lower risk of hip fractures. This may be explained based 
on differences in skeletal size between Asians and Caucasians. Areal BMD measured by DXA 
does not adjust for vertebral depth. Wider and larger vertebrae are deeper, thus not adjusting 
for depth will result in overestimation of BMD in individuals with larger skeletons.  Similarly, 
BMD is underestimated in individuals with smaller skeletons. Correcting for the differences in 




skeletal size significantly reduces the differences in BMD seen among Asians and Caucasians 
(Syed & Khan, 2002).   
 
It is important for the technologist to ensure that the appropriate race is identified when 
scanning a non-Caucasian patient, as misidentification will affect the results of the study 
(Figures 2.14 and 2.15). Standards and guidelines for the practice of densitometry have been 
developed by the ISCD, a non-profit global organisation addressing continuing medical 




Figure 2.14:  An illustration of an African-Canadian female who was mistakenly                         
identified as Caucasian (adapted from Syed & Khan, 2002) 




Upon comparison to the Caucasian young adult normative data, she was identified as having 





Figure 2.15:  An illustration of an African-Canadian female who was correctly   
                       identified as Caucasian (adapted from Syed & Khan, 2002) 
 
Upon comparison to the use of race-appropriate normative data, the patient was identified as 
having osteoporosis with a T-score of -2.6. 
 
 













This research project forms part of a larger parent study entitled: Genetic polymorphisms in 
black South Africans with type 2 diabetes mellitus (T2DM) from the central Free State area 
(ECUFS No. 162/2012).  
 
Permission was granted by the principle investigator of the above-mentioned study to access 
the data recorded. All the data collected was blinded and delinked from all personal information 
to ensure that patient confidentiality was maintained. 
 
The objective of this study was to determine the effect of T2DM on bone mineral density 
(BMD) in middle-aged Black South African women. The bone density of 91 patients 
previously diagnosed with T2DM (test group) and 49 non-diabetic volunteers (control group) 
were compared during the study. Dual-energy X-ray absorptiometry (DXA) scans were 
performed by using the Discovery W QDR Hologic Densitometer (model S/N 70494) 
evaluating the anteroposterior (AP) lumbar spine, left hip and right hip on everyone.  
 
 




3.2 Study location 
 
The Free State is a country in South Africa which covers an area of 129,825 km2.  The estimated 
population was 2,954,300 in 2018, which consists of Blacks (87,6%), Whites (8.7%), 
Coloureds (3,1%) and Indians or Asians (0,4%) (www.freestateonline.fs.gov.za). 
 
The study was conducted at Universitas Academic Hospital, Bloemfontein, involving the 
Department of Endocrinology.  The history of the Universitas Academic Hospital is interwoven 
with the history of the University of the Free State - a multi-campus public university in 
Bloemfontein, the capital of the Free State and the judicial capital of South Africa.    
 
The Universitas Academic Hospital was one of the first public-private partnerships (PPP) in 
health care in South Africa when it opened its doors in 2003.  This was the first ever  
public-private healthcare partnership of its kind in South Africa, and it is managed by Netcare.  
 
The Endocrine Clinic provides care to patients with a variety of endocrine conditions involving 
hormone function, such as Diabetes Mellitus (DM).  DXA is one of the general tests done on 
the patients attending the clinic.  DXA scans on both the test group as well as the control group 
were performed at this location. 
  
3.3 Study population 
 
In order to compare the patients previously diagnosed with T2DM with the patients not 
diagnosed with T2DM they were classified as the test group and the control group.  
 




The study population consisted of 91 urban Black female patients with a confirmed diagnosis 
of T2DM. They attended the diabetes clinic at Universitas Academic Hospital, Bloemfontein, 
South Africa, from May 2013 to July 2014. These patients were referred to as the test group in 
this study. 
 
Forty-nine volunteers with no confirmed diagnosis of T2DM (HbA1c% were <6%) were 
recruited from a local church by word of mouth acted as the control group.  All participants 
included in the control group were informed about the benefits of a DXA scan and educated 
about osteoporosis as well as  DM. 
 
Subjects for the test group were numbered from T1-T91, and subjects for the control group 
were numbered from C1-C49. 
 
All the individuals were aged ≥ 40 and ≤ 60 years and weight ≤ 130 kg.   
 
3.3.1 Study cohorts 
 
Haemoglobin A1c (HbA1c) % of all the participants were tested to confirm their diagnosis 
for DM. 
 
Test group:  Patients suitable for the test group were recruited from the diabetes 
   clinic at Universitas Hospital, with confirmation of the T2DM from 
   medical files as diagnosed with T2DM by an endocrinologist according
   to the 2012 guidelines of the Society for Endocrinology Metabolism and 
   Diabetes of South Africa (SEMDSA).   
 
   According to Amod et al. (SEMDSA, 2012) the diagnosis of diabetes 
   is confirmed in patients with symptoms of hyperglycaemia (polyuria, 




   polydipsia, blurred vision, weight loss) or metabolic decompensation 
   (diabetic ketoacidosis or hyperosmolar non-ketotic state), when any 
   one single test confirms that the:   
 
• random plasma glucose is ≥ 11.1 mmol/L;  
• fasting plasma glucose is ≥ 7.0 mmol/L;  
• haemoglobin A1c (HbA1c) is ≥ 6.5%;  
• two-hour post-load glucose is ≥ 11.1 mmol/L. 
  
However, a Glucose Tolerance Test (GTT) is rarely needed in this 
category of patient.                                         
These patients’ HbA1c% were all known to be > 6.5%. 
 
Control group: Patients suitable for the control group were recruited by word of mouth 
and adhere to the following:   
 
Amod et al. (SEMDSA, 2012) stated that HbA1c of < 6.5% is 
recommended as the cut-point for diagnosing diabetes. A value of less 
than 6.5% does not exclude diabetes diagnosed using glucose tests. A 
glucose-based measurement is desirable in individuals with HbA1c 
values close to the diagnostic cut-point (e.g. 6.0 to 6.4%).  
 
   HbA1c% of all the patients recruited for the control group was  
 < 6%. The HBA1c% was done by the National Health Laboratory 
Service, Universitas, Bloemfontein according to the standard 








3.3.2 Inclusion and exclusion criteria 
 
To address the objectives of the study, the selection criteria for the patients were based on the 
inclusion and exclusion criteria stipulated below to ensure a homogeneous population. Subjects 
were included in the study if they met the following criteria:  
  
3.3.2.1 Inclusion criteria 
 
The following inclusion criteria applied: 
 
•  Black females (as indicated in patient file), 
•  subject’s weight ≤ than 130 kg, due to the weight limit of the DXA; 
•  age, only subjects ≥40 and ≤ 60 years;  
•  subjects with HbAc1% > 6.5% included in the test group; and 
•  subjects with HbAc1% < 6% included in the control group.  
 
3.3.2.2 Exclusion criteria 
 
•  Patients not able to perform the physiological test to the satisfaction of the 
 researcher. 
•            Patients with prosthesis (e.g. hip replacements) and surgical implants in any 
 area analysed. 




•  Patients that received gastrointestinal contrast or a nuclear medicine test ≤ 72 
 hour prior to DXA scan. 
•  Pregnant subjects. 
 
3.4 Study design  
 
A retrospective analytical cohort study was performed including 91 Black South African 
females previously diagnosed with T2DM, and 49 Black South African volunteered females 
not diagnosed with T2DM that underwent a BMD test between May 2013 and July 2014.   
 
Figure 3.1 represents a summary of the study layout. The test group consists of 91 subjects 
which were subdivided into two groups according to age: 37 subjects were <50 years and  54 
subjects were ≥50.  The control group consists of 49 subjects: 26 subjects were <50 years and 
23 subjects were ≥50. The subjects <50 in both groups were diagnosed according to z-score 
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Age <50:  n=37 subjects 
Age ≥50: n=54 subjects 
Non-diabetic volunteers 
49 subjects  
Age <50:  n=26 subjects 
Age ≥50: n=23 subjects  
Data collection 
• Demographic data 
• Anthropometric data 
• DXA measurements 
Subject recruitment for the parent study 
May 2013 – July 2014 
Comparison between the 
test group and the control group 
Age <50 : Z-score 
Age ≥50 : T-score 
 




Advanced age is known to affect the quality of bone.  The aim of the study was to determine 
the effect of T2DM on BMD. Thus, age was considered only as an independent variable of the 
same age (40 – 60 years) between the test group and the control group. 
 
3.5 Data collection  




All the subjects included in the study were ≥ 40 years and ≤60 years.   
 
3.5.2 Clinical data 
 
Patients were included in the test group based on their HbA1c%, which was above 6.5%.  The 
criteria for the diagnosis of DM are ≥ 6.5% (SEMDSA, 2012).   
 
Patients were included in the control group based on their HbA1c%, which was below 6%.  
According to Amod et al, (2012) the diagnostic cut-point is 6.0% to 6.4%.  No other clinical 









3.5.3 Anthropometric data 
 
The following anthropometric data were collected during the trial. 
 
Weight (kg) 
Patients were asked to remove their shoes, socks and hair ornaments when necessary for the 
weight and height measurement. Patients’ weights were measured using a Nagata electronic 
platform scale. Weight was measured in kilogram (kg) and rounded to one digit after the 




Each patient's height was measured using a stadiometer.  The stadiometer was mounted against 
a wall.   All patients were instructed to stand up straight with their heads and heels against the 
wall. The height was measured in centimeter (cm) and rounded to one digit after the decimal 
(e.g., 121.6 cm). 
 
BMI (kg/m2) 
Body mass index (BMI) were calculated by using each patient’s height and weight.  The 
formula to calculate BMI: BMI = kilogram per square meter (kg/m2).   Kg is the person's weight 











3.6 Bone density measurement  
 
A bone density test was performed on each participant in the test and control groups.  Patients 
were asked to remove any metal objects such as buttons, cellular phones, coins, etc.  None of 
the patients had hip replacements or any surgical implants near the spine and both hips.  
 
After a new biography was created on the computer, the patients were instructed to lay down 
on their backs on the table, with their heads on the right side of the table.   
 
 
3.6.1 Bone density procedure  
 
The bone density of both hips and the lumbar spine of each patient was measured with the 
Discovery W QDR Hologic Dual Energy Absorptiometer (HOLOGIC, USA, model 
S/N70494).  
 
The Discovery W QDR Hologic was a DXA.  It was a third generation QDR densitometer that 
employed multiple detectors and a dual energy X-ray fan beam.  The arm moved in a single 
direction decreasing scan times from minutes to seconds with improved image quality and 
equivalent precision. The beam swept across a region of interest on the scan area in a fan-
shaped pattern and was detected by a high-resolution multi-detector array to form a high-
quality image (Hologic Inc., 2006).   
 
Daily quality control procedures ensured that the QDR system functions properly.   
 
 




3.6.2 Quality control 
 
The spine phantom was scanned during daily quality control (QC).  The system added the 
results of the scan to a database and plotted it on a graph.  This recorded a daily comparison to 
10 separate measurements taken at the time of the system’s installation and provided the basis 
for the system calibration.   
 
The QC Spine Phantom contained a humanlike spine segment made of a material called 
hydroxyapatite which was enclosed in a block of water-simulant epoxy. 
 
To position the spine phantom, the phantom was placed on the table with the white dot to the 
left (foot end) of the table, and aligned with the laser cross-hair, and it was verified that it was 
centred on the white dot and parallel with the phantom.  Once the phantom was properly 
positioned, the system was ready to perform the daily calibration. The QDR system 
automatically performed a system test to verify proper operation of its X-ray subsystem prior 
to scanning the spine phantom.  If the automatic system test succeeded, the system ran an auto 
QC.  When both the system test and the QC passed the BMD, values were plotted along the  
y-axis of the QC plot.  
 
3.6.3 Positioning aids 
 
The QDR series included several aids to help the operator position patients for specific 
examinations.  Positioning aids maintained the correct patient position during the acquisition 
of a scan.  They included: 
a)  Knee positioner 
b)  Hip positioner 




a) Knee positioner 
 
The large knee positioner was placed under the patient’s lower legs.  This allowed positioning 
of the femurs so that they were as close to 90 ° to the spine as possible to flatten the back.  The 
operator rotated the pillow to one of three sides to adjust for the height of the patient and length 
of their legs. 
 
b) Hip positioner 
 
The hip positioner (foot restraint) maintained the correct position of the femur, and minimised 
movement during the acquisition of a hip scan.  It was placed between the feet.  The foot and 
leg of the side being examined were rotated inwards, with the foot against the fixture.  A strap 
was placed around the foot to secure the correct position.   
 
3.6.4 Hip scan 
 
a) Performing the hip scan 
 
Positioning the patient for a hip scan involved using the foot positioner.  This positioner helped 
to align the patient’s hip, and to hold the foot firmly in place.  The foot positioner was placed 
under the patient’s legs, and the centre of the positioner was aligned with the patient’s midline. 
The patient’s entire leg was rotated (from hip socket to foot) 25 ° inward, and the radial edge 
of the foot was placed against the triangle.  The foot was flexed towards the ceiling.  The velcro 
strap was adjusted to hold the foot in the correct position.   
 
The femur was positioned to be parallel with the table edge to provide adequate space for the 
neck box.  By abducting the leg from the midline of the body the femur was straightened.  The 




cross hair of the laser was placed three inches below the greater trochanter, and 1 inch medial 
to the shaft of the femur.  [To help identify the greater trochanter, the thumb was placed on the 
iliac crest, and the fingers were spread. With the little finger directed toward the knee, the 
greater trochanter was located under the little finger.  The greater trochanter is at the same level 
than the symphysis pubis].   
 
Once the patient and C-arm were positioned correctly, the scan begun. The image was 
displayed on the screen as the scan progressed.  The scan was completed if positioned correctly, 
or repositioned if necessary. 
 
After scanning both hips, analysis was performed. 
 
b) Analysis of the hip scan 
 
The “Analysis step” buttons maximised image quality and accuracy, preventing the need for 
re-scanning.  
  
Defining the Region of Interest (ROI) 
The global ROI referred to the defined boundaries of the image that was analysed.  The ROI 
appeared on the image as a box and included the proximal femur in its entirety, the lesser 
trochanter, the top of the femoral head and the lateral side of the greater trochanter.  The pelvis 
(ischium) was deleted to prevent it from interfering with the placement of the neck box.  
Positioning the Neck Box 
The neck box was positioned by using the “Auto position” button, or by manual positioning.  
The neck box covered the femoral neck and did not include any area of the ischium, femoral 
head, or the greater trochanter. The upper outer corner was positioned at the notch of the greater 
trochanter.  The remaining three corners of the neck box remained in soft tissue.   
 




3.6.5 AP lumbar spine 
 
a) Performing the AP lumbar spine scan 
 
The goal for positioning the patient on the table was to ensure that the spine was as straight as 
possible for the scan.  The patient's lower legs were positioned on the knee positioner to ensure 
that the spine is kept flat.  The patient's pelvis and shoulders were aligned straight on the table 
pad and centred to the marks on the table pad.  The cross hair of the laser was positioned 1” to 
2” below the iliac crest and centred in the mid-line of the patient.   
 
An acceptable AP lumbar spine scan included the following: 
• The scan started in the middle of L5. 
• The iliac crest was evenly displayed in both lower corners of the image area.  
• The AP lumbar spine was centred in the middle of the scan window.  
• There were even amounts of soft tissue on each side of the spine. 
• The scan stopped where ribs were attached to T12 (usually the middle of T12). 
 
b) Analysis of the AP lumbar spine scan 
 
The “Analysis step” buttons, located on the left side of the window, allowed the operator to 
proceed through each task maximising image quality and accuracy, and preventing the need 
for re-scanning. 
 
Defining the Region of Interest (ROI) 
 
The global ROI referred to the defined boundaries of the image that was analysed.  The ROI 
appeared on the image as a box.  A properly positioned global ROI included the spine centred 




within the ROI and the top line of the ROI positioned between T12 and L1, and the bottom line 
of the ROI positioned between L4 and L5.  
 
Marking invertebral spaces 
 
Marking each invertebral space with a line allowed each individual vertebrae to be analysed 
separately.  By choosing the “Invertebral lines” button, three lines appeared on the image that 
marked the spaces.  Each line was evenly spaced between vertebrae in the space between 




“Point mode” was used to mark invertebral spaces of the scoliotic space when the line between 
the vertebral bodies was not straight. 
 
Labelling the vertebral bodies 
 
The “Results” button automatically labelled the marked vertebral bodies.  Vertebral labels were 
automatically assigned numbers starting at the top with L1 and down to L4.   
 
3.7 Data recorded 
 
The World Health Organization (WHO, 1994) defined osteoporosis by BMD at the hip, lumbar 
spine or forearm.  The hip and spine are the two most commonly used skeletal sites.   
 




Different bones and skeletal sites within bones have different ratios of cortical to trabecular 
bone.  The vertebrae are composed of cortical to trabecular bone in a ratio of 25:75. This ratio 
is 50:50 in the femoral head (Clarke, 2008). 
 
The difference between the test group and the control group on the spine, left hip and the right 
hip was evaluated on the BMD, T-score and the Z-score of specific site areas (Table 3.1). 
 
 
Table 3.1 Scan sites and the area measured on each site  
 
SCAN SITE SITE AREA CHART REFERENCES 
Left Hip 
Left Femoral Neck Bone Mineral Density 
Left Femoral Neck T-score 
Left Femoral Neck Z-score 
Left Total Hip BMD 
Left Total Hip T-score 








Right Femoral Neck Bone Mineral Density 
Right Femoral Neck T-score 
Right Femoral Neck Z-score 
Right Total Hip BMD 
Right Total Hip T-score 















[LFN: Left Femoral Neck; LTH: Left Total Hip; RFN: Right Femoral Neck; RTH: Right Total Hip; BMD: Bone 
Mineral Density; T-score: Comparison of the patient's BMD to the mean peak bone mass]   
  




3.8 Statistical analysis 
 
Data from the data collection sheet was captured electronically in Microsoft Excel by the 
researcher, and double checked for accuracy.  Any further analysis was done using SAS 
Version 9.2.  The Shapiro-Wilk test was performed to determine if numerical variables 
followed a normal distribution or not. Descriptive statistics namely means and standard 
deviations (SD), or median and percentiles were calculated for numerical data, whilst 
frequencies and percentages were calculated for categorical data.  To compare the test and 
control groups, analytical statistics were calculated, namely the independent T-test to test for 
differences between mean values, and the Mann Whitney U-test to test for differences between 
the median values. A significance level (α) of 0.05 was used, where p  0.05 indicates no 
significant difference in the mean or median values of the two groups, and p < 0.05 indicates 
significant difference in the mean or median values of the two groups. 
 
By interpreting the p-value from the Shapiro-Wilk test a conclusion could be made. 
 
Interpretation of the p-value: 
• If p < 0.05 then the distribution of the variable does not follow a normal distribution. 
• If p ≥ 0.05 then the distribution of the variable does follow a normal distribution. 
 
To compare the age distribution between the test group and the control group, the Mann 
Whitney U-test was performed to determine the median and quartile values. 
 
Interpretation of the p-value: 
• If p < 0.05 then there is a significant difference between the median values in the two 
groups. 
• If p ≥ 0.05 then there is no significant difference between the median values in the two 
groups. 




Interpretation of the 95% Confidence Interval (CI) of the difference between the means: 
• If 0 is included in the CI, then there is no significant difference in the mean values of 
the two groups. 




To differentiate between the T-score and the Z-score, the subjects in the test group and the 
control group were divided into two subgroups according to their age:  T-score values for 
subjects ≥50 years and Z-score values for subjects <50 years of age were used in the 
calculations. Analytical statistics, namely the Fisher’s exact test, was used to compare 
percentages in the two groups. A significance level (a) of 0.05 was used. 
 
Interpretation of the p-value: 
• If p<0.05 then there is a significant difference between the proportions of the two 
groups. 




3.9 Ethical aspects  
3.9.1 Ethical clearance 
 
The study only commenced after ethical approval was granted by the Ethics Committee of the 
University of the Free State (ECUFS 162/2012E). The project was presented to the Health 
Sciences Research Ethics Committee (HSREC) at the University of the Free State (UFS) as a 
sub-study of ECUFS162/2012E:  Genetic polymorphisms in Black South Africans with Type 
2 Diabetes Mellitus from the central Free State area (see Appendix A). 




A letter for permission to use the DXA data was obtained from the principle investigator of 
ECUFS162/2012E (see Appendix B). 
 
3.9.2 Good clinical practice (GCP) / Quality assurance 
 
All clinical work conducted during this research project was subjected to the Good Clinical 
Practice (GCP) guidelines.  The Declaration of Helsinki's basic principle number 3 states that 
research should be conducted only by scientifically qualified people and under the supervision 
of adequately qualified employees involved (South African Good Clinical Practice Guidelines, 
2006; World Medical Association Declaration of Helsinki, 2013).  Fundamentally GCP 
requires oversight of the local ethics committee, verification of the investigator's qualifications, 
a study protocol, informed consent and essential documentation needed to undertake the study, 
monitoring, submission of reports and maintenance of records.  By applying GCP guidelines 
in this research study provides public assurance that the rights, safety and well-being of the 




Personal details of patients participating in this study were kept confidential as far as possible.  
At no time during the research was the identity of any of the patients revealed to persons that 
were not part of the research team.  The parent data were delinked from all personal 
information, thus preventing disclosure of the patients’ personal details, always ensuring 
patient confidentiality.   






Patients signed a written consent form at the commencement of the parent study, which 






















This chapter represents the demographic, clinical, anthropometric and bone mineral density 
(BMD) measurements recorded for the 140 women receiving dual-energy X-ray 
absorptiometry (DXA) scans, and who participated in the research study.  Ninety-one subjects 
were previously diagnosed with type 2 diabetes mellitus (T2DM), and acted as the test group, 
and 49 subjects had no diagnoses of T2DM, and acted as the control group. Diagnosis was 
based on haemoglobin A1c (HbA1c) %. Subjects where it was known that the HbA1c% was 
>6.5% were included in the test group, and subjects with a known HbA1c% <6% were included 
in the control group.  
 
The test group and the control group were compared in the calculations for the T-score 
according to the guidelines of the World Health Organization (WHO): Normal ~ T-score at -
1.0 and above; low bone mass (osteopenia) ~ T-score between -1.0 and -2.5; Osteoporosis ~ T-
score at or below -2.5.  
 
To accommodate the National Osteoporosis Foundation of South Africa (NOFSA, 2017), the 
test group and control groups were further divided into two subgroups according to age. 
Subjects ≥50 years were added in the calculations for T-score, and subjects <50 years were 




added in the calculations for Z-score:  within the expected range for age~ Z-score above -2.0; 
below the expected range for age ~ Z-score below -2.0. 
 
No medical and disease progression history were captured during this study.   
 
Data from the data collection sheet were captured electronically in Microsoft Excel by the 
researcher, and double checked for accuracy.  Any further analysis was done using SAS 
Version 9.2.  The Shapiro-Wilk test was performed to determine if numerical variables (age, 
height, weight, body mass index (BMI), T-score, Z-score and BMD) followed a normal 
distribution, or not. Descriptive statistics namely means and standard deviations (SD), or 
median and percentiles were calculated for numerical data, and frequencies and percentages 
were calculated for categorical data (mean difference, 95% CI for mean difference, p-value, 
W-statistics). To compare the test and control groups, analytical statistics were calculated, 
namely the independent T-test to test for differences between mean values, and the Mann 
Whitney U-test to test for differences between the median values. A significance level (α) of 
0.05 was used where p  0.05 indicates no significant difference in the mean or median values 
of the two groups and p < 0.05 indicates significant difference in the mean or median values 
of the two groups.  The Fisher’s exact test was used to compare percentages of the T-score and 
Z-score in the two groups. A significance level (a) of 0.05 was used, where p ≥ 0.05 indicates 
no significant difference between the proportions of the two groups, and p < 0.05 indicates a 












4.2 Demographic, clinical, anthropometric and bone density measurements 
4.2.1 Demographic data 
 
Considering that this was a retrospective study, the data of all the subjects (n=140) were used 
in the appropriate groups. The sample population consists of a test group (n=91) and a control 
group (n=49), as represented in Figure 4.1.  The ratio of participants in the test and the control 




Figure 4.1:  Schematic presentation of the sample distribution: Test group (n=91: T2DM)  
                    vs. control group (n=49: non-diabetics) 
 
The demographic and anthropometric data of each subject are contained in Table 4.1 (test 







Test group (n=91) Control group (n=49)




Table 4.1:  The demographic and anthropometric data of the test group (n=91) 








T1 53 64,2 153,5 27,2 
T2 54 109,9 153,9 46,4 
T3 53 117,4 156,8 47,8 
T4 55 86,6 159,5 34 
T5 55 108,2 162 41,2 
T6 45 116,1 164,5 42,9 
T7 52 83 158 33,2 
T8 51 82 149 36,9 
T9 43 120,6 165 44,3 
T10 43 82 162,2 31,2 
T11 58 104 152 45 
T12 55 94,4 161,2 36,3 
T13 41 106,4 167,6 37,9 
T14 57 94,2 152,5 40,5 
T15 52 114,9 156,7 46,8 
T16 59 73,5 151,3 32,1 
T17 54 80,7 153,2 34,4 
T18 57 125,5 156,6 51,2 
T19 52 53,4 141,5 26,7 
T20 60 118,3 156 48,6 
T21 40 53,1 152,9 22,7 
T22 48 105,6 155 44 
T23 46 87,6 160,5 34 
T24 54 84,7 161 32,7 
T25 57 122,9 158,6 48,9 
T26 49 56,3 158,6 22,4 
T27 51 96,8 165,7 35,3 
T28 60 82,5 157,2 33,4 
T29 59 87 155,5 36 
T30 59 74,8 151,5 32,6 
T31 46 52,3 155,9 21,5 
T32 56 128,1 166 46,5 
T33 60 121,4 162 46,3 
T34 52 79,4 157,2 32,1 
T35 50 60,9 152,3 26,3 
T36 50 130,5 161,2 50,2 
T37 51 101,4 151,1 44,4 
T38 49 105,9 159,6 41,6 
T39 56 84,8 172 28,7 
T40 59 93,3 152 40,4 
T41 58 92 153 39,3 
T42 44 79,2 151,8 34,4 
T43 48 82,8 158,1 33,1 
T44 59 80 149,5 35,8 




T45 53 101,9 160 39,8 
T46 46 86,1 162,3 32,7 
T47 41 60 153 25,6 
T48 51 93,9 147 43,5 
T49 57 81,5 153 34,8 
T50 47 73,3 164 27,3 
T51 60 88,8 150 39,5 
T52 40 127,1 156,1 52,2 
T53 52 66,5 159 26,3 
T54 41 117,5 163 44,2 
T55 60 121,2 156,7 49,4 
T56 56 76,7 145 36,5 
T57 44 52,3 148 23,9 
T58 55 98,4 158 39,4 
T59 54 121,5 169 42,5 
T60 60 82 145 39 
T61 49 96,2 157,7 38,7 
T62 55 74,7 163,5 17,8 
T63 45 83,8 163 31,5 
T64 57 70,8 150 31,5 
T65 54 78 154 32,9 
T66 59 89,2 162,5 33,8 
T67 49 84 159 33,2 
T68 41 73,5 152 31,8 
T69 49 60,5 152 26,2 
T70 55 63 146 29,6 
T71 41 69,5 164 25,8 
T72 46 100,4 156 41,3 
T73 47 66,9 161 25,7 
T74 58 90,3 155,5 37,3 
T75 60 73,7 151 32,3 
T76 41 123,6 159 48,9 
T77 47 89 155 37 
T78 53 72,8 170 25,2 
T79 46 69,8 156 28,7 
T80 41 79,3 157 32,2 
T81 44 98 160 38,3 
T82 41 69,8 160 27,3 
T83 56 59,9 155 24,9 
T84 59 125,2 162 47,7 
T85 44 82 162,2 31,2 
T86 48 100,1 166 36,3 
T87 49 74,5 158 29,8 
T88 50 83,5 156 34,3 
T89 51 79,9 154 33,7 
T90 47 100,9 167 36,2 
T91 42 75,4 149 34 




Table 4.2:  The demographic and anthropometric data of the control group (n=49) 








C1 47 67,2 160 26,2 
C2 45 76,8 157 31,2 
C3 49 85,5 157 34,7 
C4 52 80,8 156 33,2 
C5 58 83,2 167 29,8 
C6 43 83,7 160 32,7 
C7 59 51,7 148 23,6 
C8 52 86,9 152 37,6 
C9 52 67,5 146 31,7 
C10 44 76,3 157 31 
C11 53 93,7 154 39,5 
C12 52 102,2 157 41,5 
C13 53 94,5 166 34,3 
C14 57 83,9 149 37,8 
C15 46 105 180 32,4 
C16 59 102 169 35,7 
C17 44 73,1 157 29,7 
C18 45 80,7 150 35,9 
C19 41 73,9 161 28,5 
C20 56 111,9 162 42,6 
C21 46 97,3 152 42,1 
C22 50 77,4 158 31 
C23 51 66 150 29,3 
C24 43 107,7 153 46 
C25 58 79,2 158 31,7 
C26 53 85,9 151 37,7 
C27 43 75,3 158 30,2 
C28 54 87,2 162 33,2 
C29 41 109,8 151,5 47,8 
C30 52 81,3 170 28,1 
C31 41 91,1 154 38,4 
C32 45 88,9 157 36,1 
C33 45 72,2 163,5 27 
C34 43 65,9 161 25,4 
C35 40 52,2 161 20,1 
C36 49 112,7 163 42,4 
C37 49 67 164 24,9 
C38 41 59,7 149 26,9 
C39 41 114 162 43,4 
C40 46 96,6 156 39,7 
C41 49 71,1 154 30 
C42 48 69,5 154 29,3 
C43 57 76,4 153 32,6 
C44 59 109,6 164 40,7 




C45 53 95,8 163 36,1 
C46 54 60,6 162 23,1 
C47 59 99,5 151,5 43,4 
C48 46 75,8 166 27,5 
C49 56 85,7 164 31,9 
 
The Shapiro-Wild test was used to investigate the normality of the numerical demographic 
variables (age, weight, height and BMI) within the two groups.   
 
Table 4.3:  Test of normality for the age (years) distribution within the test group, control 
                   group and the total group 
Group W-statistics p-value 
Test (n=91) Wdm: 0.943313 0.00006 
Control (n=49) Wc: 0.941292 0.0166 
Total (n=140) Wtot: 0.946445 < 0.00001 
Wdm: W-statistics of DM group; Wc: W-statistics of control group; W-statistics of the total 
group. 
 
According to the Shapiro-Wilk test of normality, the distribution of the age of the participants 
for the test group, control group and the total group did not follow a normal distribution (Wdm 
= 0.943; p = 0.0006: Wc = 0.941; p = 0.0166: Wtot = 0.946; p = <0.000 respectively), where p 
< 0.05 for all groups. Since the distribution of the age of the participants was skewed, the 
median and inter-quartile range were reported on, and the Mann Whitney U-test was used to 
compare median values in the two groups. 
 
The age for subjects included in the test group varied, from the youngest being 40 years, and 
the oldest 60 years of age, as seen in Table 4.4 below.  Subjects included in the control group 
varied from the youngest being 40 years, and the oldest 59 years of age. The median age of the 
test group was 52 years, and the median age for the control group was 49 years.  There was no 
significant difference between the median age values of the two groups (p = 0.0954).  




Table 4.4:  Descriptive statistics of the age (years) of the test group and the control group 
Group Median Inter-Quartile Range 
(IQR) 
Minimum Maximum p-value 
Test (n=91) 52.00 46.00 – 56.00 40.00 60.00  
0.0954 
Control (n=49) 49.00 45.00 – 53.00 40.00 59.00 
 
 
4.2.2 Clinical data  
 
HbA1c% levels of all the subjects for the parent study were tested according to the guidelines 
provided by Amod et al. (SEMDSA, 2017).  These guidelines require HbA1c% ≥6.5% to be 
diagnosed with diabetes mellitus (DM).  The subjects in the test group were all known to be 
>6.5% HbA1c%.  The guidelines indicate that the cut-point of HbA1c% is 6.0% to 6.4%.  
The subjects HbA1c% in the control group was known to be <6%.   
 
Unfortunately, no data were collected regarding medical history, e.g. insulin use, time since 
diagnosis, possible previous fractures, menopause, alcohol intake, smoking history, etc.  
 
4.2.3 Anthropometric data  
 
The Shapiro-Wilk test of normality was used to investigate the distribution of the variables 
(weight, height and BMI) in the test group, control group and the total group, and the results 
are tabulated in Table 4.5 below. 




Table 4.5:  Test of normality for the weight, height and BMI distribution within the test 
                   group, control group and the total group 
Variable Group W-statistics p-value 
Weight (kg) 
Test (n=91) 0.96466 0.0143 
Control (n=49) 0.976239 0.4197 
Total (n=140) 0.974267 0.0095 
Height (cm) 
Test (n=91) 0.996854 0.9992 
Control (n=49) 0.965849 0.1647 
Total (n=140) 0.990386 0.4522 
BMI (kg/m2) 
Test (n=91) 0.981975 0.2406 
Control (n=49) 0.984408 0.7564 
Total (n=140) 0.985931 0.1635 
 
According to the Shapiro-Wilk test of normality, the weight distribution of the control group 
followed a normal distribution, whilst the weight distribution for the test group and the total 
group was skewed.  Therefore, the median and IQR were reported on, and the Mann Whitney 
U-test was used to compare the median values of the test and control groups. 
 
The distribution for the height and the BMI was both normal for the test group, control group 
and the total group (p > 0.05).  The mean and SD were reported on, and the independent T-test 
was used to compare the mean values of the test and control groups. 
 




The descriptive statistics of the weight are captured in Table 4.6.  The median weight of the 
test group was 84.7kg, and the median weight of the control group was 83.2kg. There was no 
significant difference between the mean weight values of the two groups (p = 0.2107). 
 
Table 4.6:  Descriptive statistics of the weight (kg) of the test group and the control group 
Group Median  (IQR) Minimum Maximum p-value 
Test 
(n=91) 




83.20 73.10 – 95.80 51.7 114.0 
 
The descriptive statistics regarding height and BMI for the test and control groups are tabulated 
in Table 4.7. The mean height of the test group was 157.07cm, and the mean height of the 
control group was 158.17cm. There was no significant difference between the mean height 
values of the two groups (p = 0.3191). The mean BMI of the test group was 35.81kg/m2, and 
the mean BMI of the control group was slightly lower at 33.58kg/m2. There was no significant 
















Table 4.7:  Descriptive statistics of the height and BMI of the test group and the control  
                   group 


















33.58 6.38 20.1 47.8 
 
The BMI of the participants were classified into four classes, namely obese (BMI ≥ 30kg/m2), 
overweight (BMI between 25 kg/m2 and 29.9 kg/m2), normal (BMI between 18.6 kg/m2 to 24.9 
kg/m2) and underweight (BMI ≤ 18.5 kg/m2). The BMI distribution of the test group and the 
control group is demonstrated in Figure 4.2. This figure indicates that 77% of the test group 
was obese, and 16% was overweight. The control group consisted of 69% obese participants 
and 27% overweight participants. 
 





Figure 4.2:  Health distribution according to BMI classification 
 
4.2.4 Bone density measurements 
 
Areal BMD is expressed in absolute terms of grams of mineral per square centimeter scanned 
(g/cm2).  
 
Bone density of the left hip and the right hip were evaluated on the following parameters:  the 
femoral neck BMD, total hip BMD, femoral neck T-score, femoral neck Z-score, total hip  
T-score, and total hip Z-score. 
 
Bone density at the lumbar spine was evaluated from the first to the fourth lumbar vertebrae 
on the test group as well as the control group.  The regions of interest were:  Anteroposterior 








Test group (n=91) Control group
(n=49)
Obese BMI 30>kg/m2 % 77% 69%
Overweight BMI 25-29,9kg/m2 % 16,00% 27%
Normal BMI 18,6-24,9kg/m2 % 6% 4%
Low BMI <18,5kg/m2 % 1% 0%
BMI Classification
Low BMI <18,5kg/m2 % Normal BMI 18,6-24,9kg/m2 %
Overweight BMI 25-29,9kg/m2 % Obese BMI 30>kg/m2 %




The Shapiro-Wilk test of normality was used to investigate the distribution of the BMD at each 
site in the test group, control group and the total group, and the results are tabulated in Table 
4.8 below. Normality was rejected if the p-value was p <0.05.  
 
Table 4.8:  Test of normality for the BMD distribution of each site within the test group,   
                   control group and the total group 
Site Group W-statistics p-value 
LFN 
Test (n=91) 0.970077 0.0342 
Control (n=49) 0.966339 0.1724 
Total (n=140) 0.971483 0.0050 
RFN 
Test (n=91) 0.980695 0.1961 
Control (n=49) 0.982625 0.6787 
Total (n=140) 0.986476 0.1865 
LTH 
Test (n=91) 0.985695 0.4230 
Control (n=49) 0.971935 0.2886 
Total (n=140) 0.987622 0.2448 
RTH 
Test (n=91) 0.98822 0.5927 
Control (n=49) 0.978289 0.4958 
Total (n=140) 0.993333 0.7602 
AP Spine 
Test (n=91) 0.983904 0.3248 
Control (n=49) 0.972636 0.3073 
Total (n=149) 0.993411 0.7684 
[LFN: Left Femoral Neck; RFN: Right Femoral Neck; LTH: Left Total Hip; RTH: Right Total Hip]  




According to the Shapiro-Wilk test of normality, the BMD distribution at each site followed a 
normal distribution, except for the BMD distribution of the LFN of the test group and the total 
group, which was skewed.  The mean and SD of the BMD at each site were reported on. The 
mean differences in BMD and 95% CI for the mean difference in BMD between the test and 
control groups for each site were calculated. The independent T-test was used to compare the 
mean BMD values of the test and control groups. 
 
The descriptive statistics of the BMD of the different sites are summarised in Table 4.9. The 
mean LFN BMD of the test group was 0.8725 g/cm2, and the mean LFN BMD of the control 
group was 0.8787g/cm2.  The mean RFN BMD of the test group was 0.8839 g/cm2, and the 
mean RFN BMD of the control group was 0.8783/cm2.  The mean LTH BMD of the test group 
was 1.0603 g/cm2, whilst the mean LTH BMD of the control group was 1.0443 /cm2.  The 
mean RTH BMD of the test group was 1.0616 g/cm2, and the mean RTH BMD of the control 
group was 1.0240 /cm2.  The mean AP Spine BMD of the test group was 0.9811 g/cm2, whilst 
the mean AP Spine BMD of the control group was 0.9948/cm2.  To conclude, none of the mean 



















Table 4.9: Descriptive statistics of the BMD of the test group and the control group 
 
TEST GROUP  
(n=91) 
CONTROL GROUP  
(n=49) 
Variable Mean SD Min Max  Mean SD Min Max  
LFN BMD 
(g/cm2) 
0.8725 0.1612 0.4370 1.3730 0.8787 0.1696 0.5450 1.3170 
RFN BMD 
(g/cm2) 
0.8839 0.1571 .05750 1.3200 0.8783 0.1589 0.5600 1.2410 
LTH BMD 
(g/cm2) 
1.0603 0.1491 0.7450 1.3800 1.0443 0.1626 0.7230 1.4210 
RTH BMD 
(g/cm2) 




0.9811 0.1536 0.6630 1.3590 0.9948 0.1516 0.5340 1.2820 
[LFN: Left Femoral Neck; RFN: Right Femoral Neck; LTH: Left Total Hip; RTH: Right Total Hip; BMD: Bone 
Mineral Density]  
 
Figure 4.3 below is a presentation of only the mean BMD values of the different sites for the 











[BMD: Bone mineral density; g/cm2: gram per centimeter square; LFN: Left Femoral Neck; RFN: Right Femoral 
Neck; LTH: Left Total Hip; RTH: Right Total Hip] 
 
Figure 4.3:  Mean BMD values of the hips and AP spine measurements for the test group   
                    and the control group 
 
The mean differences in BMD (test – control) and 95% CI for the mean difference in BMD 
between the test and control groups for each site are shown in Table 4.10 below. The 





























Mean BMD(g/cm2) of the hips and spine 
measurements
Test group vs. control group
Test group
Control group




Table 4.10:  Difference in BMD between the test group and the control group 
Variable Mean difference 





0.0061 -0.0514; 0.0636 0.8336 
RFN BMD 
(g/cm2) 
0.0056 -0.0609; 0.0496 0.8408 
LTH BMD 
(g/cm2) 
-0.0376 -0.0699; 0.0379 0.1606 
RTH BMD 
(g/cm2) 




0.0137 -0.0399; 0.0673 0.6140 
[BMD: Bone Mineral Density; g/cm2; LFN: Left Femoral Neck; LTH: Left Total Hip; RFN: Right Femoral Neck; 
RTH: Right Total Hip] 
 
As seen in Table 4.10, none of the mean differences in the BMD values between the test group 
and the control group of the different sites showed a significant difference (all p > 0.05).  
 
The T-score represents the SD by which the BMD differs from the mean BMD of a young adult 
reference population of the same ethnicity and sex (Lorente-Ramos, 2011). Hough et al. (2010) 
explained that, when SD units are used in relation to the young adult population, this is referred 
to as the T-scores.  The classification of BMD is normal when the T-score is at -1.0 and above; 
osteopenia (low bone mass) occurs when the T-score is between -1.0 and -2.5; and osteoporosis 
is present when the T-score is ≤-2.5 (WHO, 1994).   
 




The Shapiro-Wilk test of normality was used to investigate the distribution of the T-score at 
each site in the test group, control group and the total group, and the results are tabulated in 
Table 4.11 below. 
 
Table 4.11:  Test of normality for the T-score distribution for the test group, control  
                     group and the total group:  Overall T-score approach 
Site Group W-statistics p-value 
LFN 
Test (n=91) 0.968561 0.0267 
Control (n=49) 0.965787 0.1637 
Total (n=140) 0.970477 0.0040 
RFN 
Test (n=91) 0.980157 0.1797 
Control (n=49) 0.982461 0.6715 
Total (n=140) 0.986031 0.1675 
LTH 
Test (n=91) 0.985347 0.4023 
Control (n=49) 0.970641 0.2568 
Total (n=140) 0.986809 0.2020 
RTH 
Test (n=91) 0.987934 0.5720 
Control (n=49) 0.980083 0.5687 
Total (n=140) 0.992822 0.7054 
AP Spine 
Test (n=91) 0.983931 0.3261 
Control (n=49) 0.971738 0.2836 
Total (n=149) 0.992848 0.7082 
[LFN: Left Femoral Neck; RFN: Right Femoral Neck; LTH: Left Total Hip; RTH: Right Total Hip]  




According to the Shapiro-Wilk test of normality the T-score distribution at each site followed 
a normal distribution, except for the T-score distribution of the LFN of the test group and the 
total group, which was skewed.  The mean and SD of the T-score at each site were reported on. 
The mean differences in T-scores and 95% CI for the mean difference in T-scores between the 
test and control groups for each site were calculated. The independent T-test was used to 
compare the mean T-score values of the test and control groups. 
 
Descriptive statistics of the T-score of the different sites between the test group and the control 
group are summarised in Table 4.12.  The mean LFN T-score of the test group was 0.2077, and 
the mean LFN T-score of the control group was 0.2633. The mean RFN T-score of the test 
group was 0.3143, and the mean RFN T-score of the control group was 0.2673.  The mean 
LTH T-score of the test group was 0.9692, compared to the mean LTH  
T-score of the control group, which was 0.8449.   The mean RTH T-score of the test group was 
0.9802, and the mean RTH T-score of the control group was 0.6816. The mean AP Spine  
T-score of the test group was -0.600, whilst the mean AP Spine T-score of the control group 
was -0.4796.  To conclude, none of the mean T-score values of the different sites between the 
















   










CONTROL GROUP          
 (n=49) 
Variable Mean SD Min Max Mean SD Min Max 
LFN       
T-score 0.2077 1.4542 -3.7000 4.7000 0.2633 1.5275 -2.7000 4.2000 
RFN      T-
score 
0.3143 1.4135 -2.5000 4.2000 0.2673 1.4273 -2.6000 3.5000 
LTH        
T-score 
0.9692 1.2267 -1.6000 3.6000 0.8449 1.3290 -1.8000 3.9000 
RTH      T-
score 
0.9802 1.1839 -1.8000 3.9000 0.6816 1.3244 -2.0000 4.5000 
AP Spine -0.600 1.3943 -3.5000 2.8000 -0.4796 1.3847 -4.7000 2.1000 
[LFN: Left Femoral Neck; RFN: Right Femoral Neck; LTH: Left Total Hip; RTH: Right Total Hip; T-score: 
Comparison of the patient's BMD to the mean PBM; g/cm2: gram per centimeter square]  
 
Figure 4.4 below is a presentation of the mean T-score of the different sites for the test group 
and the control group. 
 





[LFN: Left Femoral Neck; RFN: Right Femoral Neck; LTH: Left Total Hip; RTH: Right Total Hip] 
Figure 4.4:  Mean T-score of the hips and AP spine measurements for the test group and    
                    the control group 
 
The mean differences in T-score (test – control) and 95% CI for the mean difference in T-score 
between the test and control groups for each site are shown in Table 4.13 below. The 






















LFN RFN LTH RTH SPINE
REGIONS OF INTEREST
Mean T-score of the hips and AP spine 
measurements.
Test group vs control group 
Test group Control group




Table 4.13:  Difference in T-score between the test group and the control group 
Variable Mean difference 
95% CI for mean 
difference 
p-value 
LFN 0.0556 -0.4630; 0.5741 0.8325 
RFN -0.0469 -0.5439; 0.4500 0.8521 
LTH -0.1243 -0.5669; 0.3183 0.5795 
RTH -0.2986 -0.7311; 0.1340 0.1745 
AP Spine 0.1204 -0.3669; 0.6078 0.6259 
[LFN: Left Femoral Neck; LTH: Left Total Hip; RFN: Right Femoral neck; RTH: Right total hip; T-score – 
comparison of the patient's BMD to the mean peak bone mass] 
 
 
As seen in Table 4.13, none of the mean differences in the BMD values between the test group 
and the control group of the different sites showed a significant difference (all p > 0.05).  
 
The T-score is an expression of SDs of current BMD relative to young adult BMD.  The  
T-score is primarily used to diagnose osteoporosis in postmenopausal women.  T-score was 
defined according to WHO (1994) criteria for osteopenia: T-score of <-1 and >-2.5 and 
osteoporosis: T-score of ≤-2.5. 
 
The prevalence of osteoporosis and osteopenia in the test group and the control group is 











[LFN: Left Femoral Neck; RFN: Right Femoral Neck; LTH: Left Total Hip; RTH: Right Total Hip] 
 
Figure 4.5: Prevalence of osteoporosis vs. osteopenia in the test group and the control 
 
                    group in different regions                                                       
 
Taking into consideration that osteoporosis is a major health disease, Figure 4.5 indicates that 
osteopenia is a higher risk factor than osteoporosis for the middle-aged Black South African 
population. Osteopenia was more prevalent than osteoporosis in the test group as well as in the 
control group. The femoral neck and the AP spine were more susceptible for bone weakening, 
which indicate that the quality of bone would deteriorate more in the femoral neck and spine 
regions. It seems that subjects diagnosed with T2DM have similar risks for osteopenia than 
subjects not diagnosed with T2DM. 
 
With regards to the NOFSA (2017) guidelines the results of the T-score and Z-score 
classification for osteoporosis according to age were compared between the test group and the 
control group.  The following data were captured after dividing the test group and the control 


























Prevalence of osteoporosis vs. osteopenia
Test group (N=91) Osteoporosis Control group (N=49) Osteoporosis
Test group Osteopenia Control group Osteopenia




The results for women ≥50 years according to the T-score as recommended by the NOFSA 
(2017) guidelines are tabulated in Table 4.14.   
 
Table 4.14:  Diagnosis for women ≥50 years between the test group and the control 
                     group according to T-score 




T > -1 ≤ 2.5 
Osteoporosis 




T > -1 ≤ 2.5 
Osteoporosis 

































































[LFN: Left Femoral Neck; RFN: Right Femoral Neck; LTH: Left Total Hip; RTH: Right Total Hip] 
 
The Fisher’s Exact Test showed no significant difference between the proportions of the 
different groups, except at the RFN, where p < 0.05. 
 
NOFSA (2017) recommend diagnosis for women <50 years according to the Z-score, as seen 










Table 4.15:  Diagnosis for women < 50 years between the test group and the control  
                     group according to the Z-score 
Variable Test group (n=37) 
 
Control group (n=26) 
 
P-value 
 Normal:                               
Z-score ≥-2 
Below expected    
range: Z-score < -2 
Normal:     
Z-score > -2                              
Below expected 










































[LFN: Left Femoral Neck; RFN: Right Femoral Neck; LTH: Left Total Hip; RTH: Right Total Hip] 
 
The results in Table 4.15 show no significant difference between the proportions of the 
























Diabetes Mellitus (DM) is a metabolic disorder with heterogeneous aetiologies which is 
characterised by chronic hyperglycaemia and disturbances of carbohydrate, fat and protein 
metabolism resulting from defects in insulin secretion, insulin action or both.  These include 
processes that include or destroy the function of the pancreatic beta cells, with consequent 
insulin deficiency, and others that result in resistance to insulin actions (insulin 
resistance/insulin insensitivity) (Amod et al., 2017).   
 
Osteoporosis is defined as a combination of reduced bone mass and altered bone quality, with 
micro-architectural abnormalities, resulting in decreased bone strength with an increased risk 
of fractures. Based on the present definition, both bone density and quality, which encompass 
the structural and material properties of bone, are important factors in the determination of 
bone strength (Jackuliak & Payer, 2014).  Classical criteria by the National Osteoporosis 
Foundation of South Africa (NOFSA, 2017) were used in this study to classify conditions of 
normal BMD, osteopenia and osteoporosis based on the T-score for subjects ≥50 years and 
Z-score for subjects <50 years. 
 




The risk factors for the onset of osteoporosis are many and different from each other. Some 
of them cannot be modified, such as age, hereditary diseases and endocrine diseases. Others 
are modifiable, so that prevention is an advisable tool to reduce the incidence of osteoporosis. 
Among preventive tools, physical activity, dietary intake, obesity, etc. are certainly valid 
instruments of prevention (Castrogiovanni et al., 2016). This highlight the importance   of 
osteoporosis education and awareness programs. Taking the above mentioned into 
consideration there is numerous actions that can be taken to prevent or limit the incidence 
osteoporosis therefore highlighting the importance of education and awareness programs. 
 
DM adversely affects the skeleton and is associated with an increased risk of osteoporosis and 
fragility fractures.  Type 1 diabetes mellitus (T1DM) affects the skeleton more severely than 
type 2 diabetes mellitus (T2DM), probably because of the lack of the bone anabolic actions of 
insulin and other pancreatic hormones. Bone mass can remain high in patients with T2DM, but 
it does not protect against fractures, as bone quality is impaired. Increased awareness of 
osteoporosis is needed in view of the growing and aging population of patients with DM 
(Hamann et al., 2012).   
 
One important way to describe bone quality is to assess its micro-architecture. Bone micro-
architecture contributes to the mechanical strength of bone and, thus, to its ability to withstand 
fractures. Bone loss is often accompanied by deterioration in bone architecture, resulting from 
a decrease in the number of trabeculae of cancellous bone, increased intertrabecular distances, 
and a loss of trabecular connectivity. In addition, a reduction in the thickness of cortical bone 
and an increase in its porosity of trabecular bone can result in fragility of the femoral neck. 
Osteoporotic bone is, hence, called “porous” (Jackuliak & Payer, 2014).  Quantitative computed 
tomography (QCT) and high-resolution peripheral QCT (HR-pQCT) are also commonly used when 
assessing bone mass and structure in patients with osteoporosis.  Amstrup et al. (2016)  stated that 
different information on bone quality is obtained, depending on the imaging technique and 
measuring site.  They suggest that the various techniques measure different characteristics of the 
bone and may therefore be used in conjunction with dual-energy X-ray absorptiometry (DXA) for 
imaging in clinical practice. 




Bone has trabecular and cortical components. Trabecular bone predominates in vertebrae and 
the proximal femur, whereas cortical bone is prominent in the long bone shafts.  Trabecular 
remodelling occurs at a rate of approximately 25% per year, while the cortical rate is 
approximately 3% per year. Thus, changes in bone mineral density (BMD) occur more quickly 
and have greater clinical implications in trabecular bone, which is consistent with the 
prevalence of vertebral and femoral fractures in patients with osteoporosis (Lash et al., 2009). 
 
Numerous studies have been done on BMD and metabolism in patients with DM and 
coexistence of this disease and osteoporosis, but controversies still exist.  The most important 
aim of this study was to compare the BMD of T2DM patients with those of non-diabetic 
middle-aged Black South African women. The results of this study indicated that there was no 
significant change in the BMD of middle-aged Black South-African women diagnosed with 
T2DM compared to non-diabetic women. 
 
There was little information to be found for this specific ethnic group.  Studies were done on 
Black South African women and diabetes, and on Black South African women with 
osteoporosis.  There was no information to be found on the effect of T2DM on BMD of Black 
South African women (Goedecke et al., 2017: Paruk et al., 2017).  The aim of their study was 
to ensure that existing treatments could be used in the best possible way should the study show 
a relationship between T2DM and BMD. 
 
5.2 Demographic, anthropometric and bone density measurements 
5.2.1 Demographic data 
 
Black South African women are not only undiagnosed and unaware, but also unable to access 
the correct education and health services, since Africa lacks sufficient resources and 
infrastructure to effectively deliver such services. Consequently, most patients are diagnosed 




after presenting complications (Issaka et al., 2018).   The data collected for this study were 
data of Black South African women to address the lack of information available for this 
population. 
 
Data received for this study were recorded for the parent study previously done:  Genetic 
polymorphisms in Black South Africans with T2DM from the central Free State area (ECUFS 
No 162/2012).  DXA was done on 140 participants.  Sixty-five per cent of these participants 
were diagnosed with T2DM and acted as the test group, and thirty-five per cent were 
volunteers with no diagnoses of T2DM, who acted as the control group (see Figure 4.1).  
Women between the age ≥ 40 and ≤ 60 years were included in this study.   
 
According to Goedecke et al. (2017), due to the ageing population, increasing urbanisation 
and the associated lifestyle changes, Sub-Saharan Africa (SSA) has the highest projected 
rates of increase in T2DM over the next 25 years. The Black South African population has a 
strong believe in their culture. Cultural perceptions regarding weight loss and limited 
financial resources are the major limitations to the management of T2DM.  Prevention is 
vital; therefore, this specific population group was included.  
 
Sotunde et al. (2015) examined the association between body composition (fat mass, lean 
mass and body mass index {BMI}) and bone health (BMD and fracture risk) in 189 healthy 
postmenopausal urban Black South African women aged ≥ 43 years.  They conclude that lean 
mass and fat mass were positively associated with femoral neck, spine and hip BMDs, and 
negatively associated with fracture risk.  Unfortunately, only 6% of the participants in the 
test group had a normal BMI, and 4% in the control group had a normal BMI, which was 
insufficient data to examine the association between BMI and BMD for this study (see Figure 
4.2). 
 
A study done in India by Kumar et al. (2015), included a test group (n=41) with T2DM and 
mean age 51.9, and a healthy control group (n=41) without T2DM and mean age 51.4 years.  
All the participants were females between 40 and 60 years of age.  The subjects in the test 




group received treatment with oral hypoglycaemic agents for a period of at least three 
consecutive years.  The mean BMI were comparable between both groups.  They found no 
significant difference between the two groups in the BMD and T-scores at the femoral neck 
and lumbar spine among T2DM patients receiving treatment and controls.  In their study the 
presence of normal BMD (9/41 vs 8/41), osteopenia 16/41 vs 18/41) and osteoporosis (16/41 
vs 15/41) was comparable between the test and control groups. 
 
Thakur and Dash (2018) conducted a study in western Odisha which included 60 diabetic 
and 60 non-diabetic subjects between 40 and 65 years of age.  They found no significant 
difference of the BMD in both groups.  On further analysis, the incidence of osteoporosis 
was higher among the diabetic subjects, whereas incidence of osteopenia was higher among 
non-diabetic subjects. Our study supports the findings of Thakur and Dash (2018) for we have 
also demonstrated no significant difference in the BMD of both groups. However, osteopenia 
was more prevalent that osteoporosis in both groups. 
 
The median age for the test group in this study was 52 years, with the youngest being 40 
years and the oldest 60 years of age.  The median age for the control group was 49 years, 
with the youngest being 40 years and the oldest 59 years of age. Although the normal 
distribution of the patients' age of both the test group and the control group was skewed 
according to the Shapiro-Wilk test, the Mann Whitney U-test showed no significant 
difference between the median values between the two groups.  It is therefore appropriate to 
assume that the age variable between the two groups are statistically similar (see Table 4.3). As 
the distribution of age was skewed, the BMD on different age intervals could not be 
determined. 
  
Compston (2017) performed a meta-analysis which only included postmenopausal women.  
She found strong evidence that T2DM is associated with an increased risk of hip fracture, 
and weaker evidence of an increased risk of wrist, spine and foot fractures. Although the risk 
for fracture was not investigated in our study there was evidence that the prevalence of 




osteopenia was higher in the AP Spine, lower in the femoral neck of both hips and the lowest 
in the total hip regions. 
 
5.2.2 Anthropometric data  
 
Due to the weight limit of the DXA (HOLOGIC W QDR, USA, model S/N70494) the 
participants weighed ≤ 130 kg.  Statistical analysis shows no notable difference in weight 
between the two groups, although the maximum weight in the test group was slightly higher  
(see Table 4.6).  The control group shows a slight increase in the minimum height as well as 
the maximum height when compared to the test group, but the mean between the two groups 
is similar (see Table 4.7).  With similar weight and height, the BMI shows no significant 
difference between the two groups. 
 
Thakur and Dash (2018) found no significant difference in the BMI of the diabetic group vs. 
the non-diabetic group and stated that the study did not signify BMI as a predictor for BMD.   
 
A study done by Adeniyi et al. (2015) investigated the prevalence and the determinants of 
overall obesity among patients with T2DM in rural and semi-urban areas surrounding the 
town of Mthatha, South Africa.  They found that 60.2% of their sample population were 
defined as obese.  After calculations of the BMI for this study group, it seems that obesity is 
a problem in the middle-aged Black South African women population.  According to Figure 
4.2, this study indicates that 77% of the test group was obese, and 16% was overweight. The 
control group consists of 69% obese participants and 27% overweight participants. 
 
A study done by Micklesfield et al. (2018) highlight the need for more tailored intervention to 
slow down the obesity epidemic in middle-aged Black South African women.  Dickie et al. 




(2016) conclude that both physical activity and cardiorespiratory fitness were associated with 
reduced total and central fat mass and reduced T2DM.   
 
Johnson and Mincey (2016) stated that obesity continues to be a public health concern across 
the globe.  They mentioned in their article that obesity has increased worldwide over the past 
2 decades.  Chooi et al. (2019) found that the worldwide prevalence of overweight and 
obesity has doubled since 1980.  They stated that obesity rates have increased in all ages and 
both sexes irrespective of geographical locality, ethnicity or socio-economic status, although 
the prevalence of obesity is generally greater in older persons and women. 
 
5.2.3 Bone density measurements 
5.2.3.1 Bone mineral density (BMD) 
 
A cross-sectional study in South Karnataka, done by Asokan et al. (2017) was conducted on 
150 patients between 40 and 70 years of age which included 75 T2DM subjects and 75 
nondiabetic subjects.  No significant difference was observed in BMD of both the groups.  This 
study shows similar results to the study conducted by Asokan et al. (2017) regarding the BMD 
between T2DM subjects and non-diabetic subjects.   
 
Investigation shows that the left femoral neck (LFN) of the test group (p = 0.0342) and the total 
group (p = 0.005) did not follow a normal distribution (see Table 4.8), and therefore the mean 
differences and 95% confidence interval (CI) were investigated (see Table 4.10).  None of the 
mean BMD values of the different sites between the two groups showed a significant 
difference.  
  
Bayani et al. (2016) investigated the relationship between osteoporosis and T2DM in elderly 
people.  They examined 1 151 elderly people in Amirkola, northern Iran, of which 31.45% 




had T2DM.  Their results demonstrated that the mean lumbar and femur BMD in older people 
with T2DM were higher than in people without DM. 
 
In an article compiled by Walsh and Vilaca (2017), they articulate that T2DM is associated 
with higher BMD, but increased overall and hip fracture risk.  They postulate that it is 
possible that, even if BMD increases in response to obesity, the capacity for increase is 
limited and eventually the load-to-strength ratio rises far enough to cause fracture in  
low-trauma injuries.  Unfortunately, no patient history of possible fractures was recorded in 




Osteopenia in the anteroposterior (AP) spine was more prevalent than in any other region.  The 
overall prevalence of osteopenia is higher than the prevalence of osteoporosis.  It seems that 
the femoral neck and AP spine are more prone to low bone mass than the total hip region (see 
Figure 4.5).  Other than the study done by Asokan et al. (2017), this study indicates that the 
incidence of osteopenia was higher compared to the incidence of osteoporosis among middle-
aged Black South African women regardless of their T2DM status. Asokan et al. (2017) found 
that the incidence of osteoporosis was higher among diabetic subjects, whereas incidence of 
osteopenia was higher among non-diabetic subjects.  The subjects were from South Karnataka.  
These findings were supported by the study carried out by Thakur and Dash (2018) in western 
Odisha. 
 
The results of this study are in accordance with a study done by Raska et al. (2017).  They 
studied the BMD of 68 postmenopausal women with T2DM and 71 controls.  In their cohort 
of 68 postmenopausal women with T2DM, 32.4 % of women had normal BMD, 48.5 % had 




osteopenia and 19.1 % osteoporosis, whilst in the non-diabetic control group it was 28.2 %, 
50.7 % and 21.1 % of subjects, respectively.  
 
When investigating the T-score between the test group (n=91) and the control group (n=49), 
there was no significant difference between the two groups (see Table 4.13).  The results for 
this study indicated that T2DM did not influence BMD for this group. 
 
On further analysis when the control group and the test group were divided according to age, 
the test group consisted of 54 subjects ≥50 years, whilst the control group consisted of 23 
subjects ≥50 years.  They were compared according to the T-score as seen in Table 4.14.  There 
was no significant difference between the proportions of the two groups, except at the right 
femoral neck (RFN), where p < 0.05. 
 
Data recorded according to the Z-score for women < 50 years in the test group consisted of 37 
subjects, and the control group consisted of 26 subjects.  There was no significant difference 




























There is limited data available on the association between type 2 diabetes mellitus (T2DM) and 
osteoporosis for middle-aged Black South African women.  T2DM is a chronic disease that 
affects several target organs (Martinez-Laguna et al., 2015).  Data on the association between 
T2DM and osteoporosis are controversial.  There was no information to be found for studies 
done to determine the effect of T2DM on bone mineral density (BMD) in Black South African 
women.  Therefore, the aim of this study was to determine the effect of T2DM on this specific 
population group. 
 
Given the current data, comparison of T2DM patients and non-diabetic controls showed no 
significant differences in BMD and T-score in the femoral neck, total hip and anteroposterior 
(AP) lumbar spine region.  Osteopenia was also more prevalent than osteoporosis in both 
groups. 
 
This study confirms the results of similar studies that there is no significant change in the BMD 
of women diagnosed with T2DM. Although the difference is not statistically significant, there 
is evidence of low bone mass (osteopenia) in general for this population.  It has been observed 
that T2DM negatively affects bone strength regardless of BMD.  According to Sanches et al. 




(2017) although T2DM patients have normal BMD, they have a greater risk for fractures.  They 
claimed that this increased risk is probably due to abnormalities in bone material strength and 
biomechanical quality.  Ahmad et al. (2016) gathered data from a large meta-analysis with a 
linkage disequilibrium using Utah residents with Northern and Western European ancestry.  
They detected a weak association between T2DM and femoral neck BMD, and no statistical 
significance between T2DM and AP spine BMD.  They suspect that the effect of T2DM on 
BMD is site-specific, and that it could relate to the known disparate effects of T2DM on cortical 
and trabecular bone and the significant regional variation in bone microstructure throughout 
the skeleton.  The results obtained from this study to determine the effect of T2DM on BMD 
in middle-aged Black South African women, confirm the possibility that BMD is site-specific.  
It seems that bone fragility in T2DM, which is not reflected by BMD, depends on bone quality 
deterioration rather than bone mass reduction.   
 
It is important to keep an open mind for the probability of future fracture risks for patients with 
T2DM.  The current osteoporosis guidelines for screening can be used for patients with T1DM 
and T2DM, but it is important to bear in mind that diabetes mellitus (DM) is a risk factor for 
osteoporosis and fracture, and that fractures can occur at higher BMD levels in patients with 
DM (Jackuliak & Payer, 2014). 
 
According to Silva et al. (2015) BMD explains only 60% - 80% of bone strength, and several 
skeletal features other than BMD contribute to bone strength and fracture risk.  BMD is not 
sensitive enough to assess the risk of osteoporotic fractures.  The aetiology of DM-related bone 












This was a retrospective study and provides limited insight to unravel underlying 
pathophysiological mechanisms of the observed relationships.   
 
It is well known that DXA techniques have its own limitations.  Further techniques, such as 
peripheral quantitative computed tomography which allows for separate assessment of the 
trabecular and cortical compartments of the bone, may provide better insight into the 
trabecular-cortical bone relationships. 
 
Shortcomings in this study: 
 
1. There was no information available regarding medical history, e.g., insulin use, 
timeframe since diagnosis, possible previous fractures, glucocorticoid treatment, bone-
active drugs, calcium intake, etc. 
2. There was no information available with regards to smoking history, nutrition, 
physical activity, etc. 
3. There was no information with regards to contraception use (e.g. oral or injectable). 
4. The population group was very small.  With a larger number of subjects more accurate 
results would represent this ethnic group. 
5. Although the subjects were all middle-aged, they should also be divided into different 
age groups to account for the natural aging process of bone. 
6. BMD does not reflect bone quality. Bone quality would be a better indication for 
future fracture risks. 
7. Current osteoporosis screening guidelines do not account for human 
immunodeficiency virus/acquired immune deficiency syndrome (HIV/AIDS) status, 
and clinical risk assessment tools are not sensitive in persons living with HIV/AIDS. 
HIV/AIDS status was not a considering factor in our study. 
 






The following recommendations can be made from this research study: 
• The study population could be increased and T1DM included. 
• Advanced scientific investigations are required to assess the bone quality in T2DM, 
which is not reflected by BMD. 
• Incorporating more than one assessment tool to evaluate the risk of fracture assessment, 
i.e., WHO fracture risk assessment tool (FRAX) algorithm and questionnaires. 
 
Additional studies are required to determine whether osteoporosis is aggravated by T2DM, and 
whether it should be considered as one of the long-term complications of diabetes. 
 
Healthcare in South Africa varies from the most basic primary healthcare, which is largely 
accessible free of charge in state hospitals and clinics.  Public healthcare is generally  
over-burdened and poorly resourced, which makes it difficult to serve most of the population.  
Many times, state patients reach advanced care settings when their conditions have progressed 
or complicated.   
 
Some risk factors for T2DM such as genetics, ethnicity and age, are not modifiable.  Others, 
such as being overweight or obese, unhealthy diet, insufficient physical activity and smoking 
are modifiable through behavioural and environmental changes. Several effective policy 
options are available to facilitate these behavioural changes, and to create supportive 
environments for healthy lifestyles, e.g., improved diet and physical activity.  
 
Diabetes prevalence, deaths attributable to diabetes and healthcare expenditure due to diabetes 
present a large social, financial and health system burden across the world.  Bommer et al. 
(2018) highlight the importance to take urgent action to prepare health and social security 
systems to mitigate the effects of diabetes.     
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